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ABSTRACT 
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal 
malignancies in the United States, with an average five-year survival rate of just 
6.7%. One unifying aspect of PDAC is mutational activation of the KRAS 
oncogene, which occurs in over 90% of PDAC. Therefore, inhibiting KRAS 
function is likely an effective therapeutic strategy for this disease, and current 
research in our lab and others is focused on identifying downstream effectors of 
KRAS signaling that may be therapeutic targets. 
miRNAs are powerful regulators of gene expression that can behave as 
oncogenes or tumor suppressors. Dysregulation of miRNA expression is 
commonly observed in human tumors, including PDAC. The mir-17~92 cluster of 
miRNAs is an established oncogene in a variety of tumor contexts, and members 
of the mir-17~92 cluster are upregulated in PDAC, but their role has not been 
explored in vivo. 
This dissertation encompasses two studies exploring the role of miRNAs 
in pancreatic tumorigenesis. In Chapter II, I demonstrate that deletion of the mir-
17~92 cluster impairs PDAC precursor lesion formation and maintenance, and 
correlates with reduced ERK signaling in these lesions. mir-17~92 deficient 
tumors and cell lines are also less invasive, which I attribute to the loss of the 
miR-19 family of miRNAs. In Chapter III, I find that Dicer heterozygosity 
inhibits PDAC metastasis, and that this phenotype is attributable to an increased 
sensitivity to anoikis. Ongoing experiments will determine whether shifts in 
particular miRNA signatures between cell lines can be attributed to this 
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phenotype. Together these findings illustrate the importance of miRNA 
biogenesis, and the mir-17~92 cluster in particular, in supporting PDAC 
development and progression.  
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CHAPTER I 
Introduction 
 
“Good men, the last wave by, crying how bright 
Their frail deeds might have danced in a green bay, 
Rage, rage against the dying of the light. 
 
[…] 
 
Grave men, near death, who see with blinding sight 
Blind eyes could blaze like meteors and be gay, 
Rage, rage against the dying of the light.” 
     - Dylan Thomas 
 
Modern science has brought us to an age of incredible momentum and progress in 
the fight against human disease. Thanks to research in fields like cancer biology, 
immunology, genetics, structural biology and metabolism, many previously 
incomprehensible illnesses can now be understood and effectively fought using therapies 
targeted with molecular and even atomic precision. 
Sadly, our achievements are still far outweighed by our failures, and our 
understanding of most disease pathophysiology is incomplete. Within human disease, 
cancer presents one of the most significant hurdles to understanding because of the 
incredible diversity of aberrations in normal biology that occurs during tumor evolution. 
For decades, scientists and clinicians have fought to gain a detailed understanding of its 
molecular underpinnings, and we have consequently amassed a tremendous literature on 
the intricacies of cancer evolution. Indeed, we have even occasionally been able to 
achieve radical breakthroughs for one malignancy or another, saving hundreds of 
thousands of lives with a single drug. These successes often arise from the discovery of a 
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proverbial Achilles’ heel, but the discovery of such an exploitable weakness is 
historically a very rare event. Moreover, most of the wonder drugs do not work for 
everyone or forever. Far more often, what we obtain through research is a fractured 
understanding of the many contributing aspects of cancer, without meaningful 
integration. Most distressingly, findings that have been robustly characterized and 
repeated in animal models commonly fail to translate across species into humans, due to 
a mistaken understanding of the context of the original data or simply due to differences 
in human and mouse biology. 
This view of our progress, highlighting the difficulties and setbacks of cancer 
biology, is certainly bleak, but I think we are now at the beginning of a new age of 
discovery. Innovations in the accumulation and curation of large biological datasets have 
allowed us to begin gathering information at an unprecedented rate. The diverse paths of 
tumor evolution guarantee the continuing diversity of tumor appearance, behavior and 
response to treatment, and to date, generalizing from this spectrum has been our greatest 
hurdle to forward progress. But with continuing advancement in genome, transcriptome, 
and proteome profiling technologies, there is hope that this diversity can be built into a 
more complex and adaptable understanding in the near future.  
I offer this as a bit of hope, because the subject of this dissertation, pancreatic 
cancer, is truly one of the most devastating and intractable cancers of modern times. 
Frustration, it is probably fair to say, is ubiquitous among researchers and clinicians, but 
the pace of progress is objectively accelerating.  
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Indeed, optimism and hope are among the most impressive attributes of the 
patients, families, clinicians and researchers who battle this disease. Speaking for 
scientists and clinicians, we learn hope from patients and their families, who are, on the 
whole, unaccountably hopeful. They care deeply about progress in research, but not in the 
way one might expect. They and their families and friends go to Capitol Hill, they speak 
at symposia, they raise funds and awareness, but they aren’t doing it for themselves. They 
have hope for their own survival, true, but they work for everyone else’s future. With 
likely less than a year to live, they know that no research can help them; for them, there 
will be no last-minute wonder drug, no last-resort surgery. There is time only to live, to 
help build a better future for those who will come after, and to hope. It is for them that we 
work so hard, and it is because of the hope that they teach us, that we can manage to do it 
at all. They and their families deserve all that we, as scientists and clinicians, can achieve. 
We are the source of their hope, and they are the cause of our determination. 
10 
 
 
Annual deaths from pancreatic cancer in the United States have remained 
unchanged at approximately 10.9 per 100,000 individuals since 1975 (Howlader et al. 
2014). This disturbing statistic derives from our inability to detect early lesions or to treat 
advanced stages of disease. Reasons for these failures originate from both the complexity 
of malignant and premalignant disease and the particular challenges posed by normal 
pancreas anatomy. In this section, we will explore what is known about the origins and 
evolution of pancreatic cancer, as well as the modern tools that facilitate our growing 
understanding and where the field hopes to make progress in the coming years. Following 
that will be a foundational discussion of the particular class of molecules, called 
microRNAs, that constitutes the focus of my research. 
 
Normal Pancreas 
The pancreas is an organ containing two distinct compartments with disparate 
functions: the endocrine and the exocrine. The endocrine pancreas comprises 1-2% of the 
mass of the organ and is distributed throughout in the form of the islets of Langerhans, of 
which an adult human has approximately one million (Weir and Bonner-Weir 2013). 
These spheres of tissue contain distinct regions of specialized cells that secrete various 
hormones into the circulation. The major cell types and their products include α-, β-, δ-, 
ε-, and PP-cells, which secrete glucagon, insulin, somatostatin, ghrelin, and pancreatic 
polypeptide, respectively (Jain and Lammert 2009). Largely, these molecules exert 
complementary effects in the regulation of blood glucose levels, and they are coordinated 
by direct cellular monitoring of blood chemistry as well as paracrine signaling between 
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cells within the islet. Interestingly, the pancreas possesses a portal circulation between the 
endocrine and exocrine compartments, such that a portion of the hormones secreted by 
some of the islets pass in relatively high concentration through the capillary beds of the 
exocrine tissue prior to circulating into the venous system (Weaver and Sorenson 1989; 
Gorczyca et al. 2010). The physiological and pathological ramifications of this ‘insulo-
acinar’ circulation remain largely unexplored, although there is an appreciation that the 
effects of insulin and somatostatin play major roles in exocrine pancreas signaling 
(Barreto et al. 2010). The lymphatic system of the pancreas, although not histologically 
prominent, has been well-described and plays a critical role in the clearance of interstitial 
fluid for the prevention of pancreatitis (Mastracci and Sussel 2012). 
The exocrine pancreas comprises the vast majority of the organ (>95%) and 
consists predominantly of acinar cells organized around a ductal network. The pancreatic 
acinar cell is highly active in secretion and is responsible for the production of large 
quantities of digestive enzymes, including trypsinogen, chymotrypsinogen, pancreatic 
lipase, and pancreatic amylase. Trypsinogen and chymotrypsinogen are secreted as 
inactive precursors categorically referred to as zymogens, which are only normally 
activated upon exposure to enteropeptidase in the intestinal lumen. This assures that 
proteolytic activity is targeted to the digestive compartment of the gut and that the 
pancreatic parenchyma is protected from enzymatic damage (Leung and Ip 2006).  
Acinar cells possess a striking histological appearance in standard hematoxylin 
and eosin stains: their extensive reservoirs of zymogen granules are eosinophilic and 
concentrated apically, whereas their extensive rough endoplasmic reticula are basally 
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located, creating a high-contrast dichromatic cell. They are organized into small clusters 
called acini (hence their name), which facilitate the efficient secretion of fluid and 
enzymes into a shared cul-du-sac of the ductal system (Figure 1.1) (Low et al. 2010; 
Reichert and Rustgi 2011). 
The ductal network begins here, in the center of the acinus, with the suitably 
named centroacinar cell. These cells begin the job of modifying the acinar secretion by 
alkalizing it with the addition of bicarbonate (Lee et al. 2012b). Alkalization of 
pancreatic secretions is continued throughout the rest of the ductal network as the 
centroacinar cells give way to the low cuboidal cells of the intercalated ducts, and thence 
to the columnar cells of the lobular and main pancreatic ducts. Alkalization and hydration 
of pancreatic juice in these ducts is dependent on the cystic fibrosis (CF) transmembrane 
receptor, which is why individuals with CF experience pancreatic insufficiency and 
pancreatitis (Ishiguro et al. 2012). The main pancreatic duct combines with the common 
bile duct, which passes through the head of the pancreas on its journey from the liver, and 
this common duct then travels a very short distance and empties into the duodenum 
through the Sphincter of Oddi. 
When nutrients are detected by enterocytes in the small intestine, it stimulates 
enterocytes to secrete cholecystokinin-releasing peptide onto nearby I-cells in a paracrine 
fashion. I-cells then secrete cholecystokinin (CCK) into the circulation, resulting in the 
coordinated relaxation of the Sphincter of Oddi, stimulation of acinar cell secretion, and 
constriction of the gall bladder (Niederau et al. 1994; Rehfeld 2011). The activity of CCK 
is regulated by exocrine and endocrine feedback loops. Its activity is hormonally  
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antagonized by the action of pancreatic peptide and somatostatin, secreted by PP- and δ-
cells. CCK release from I-cells is also inhibited through trypsin-mediated digestion of 
CCK-releasing peptide in the intestinal lumen (Miyasaka et al. 1989). This arrangement 
allows the carefully coordinated storage and release of secretions from the pancreas and 
gall bladder, ensuring optimal digestion and assisting in glucose homeostasis.  
This anatomical arrangement also has ramifications for disease. In the event of 
ductal obstruction, backup of pancreatic enzymes or bile can occur. Stasis of pancreatic 
secretions causes pancreatitis from the action of digestive enzymes on the pancreatic 
parenchyma, and bile stasis causes jaundice, which is the backup of the yellow waste 
pigment bilirubin into systemic tissues. These obstructive effects can occur due to 
primary idiopathic or hereditary pancreatitis, gall stones, cystic fibrosis, and pancreatic 
cancer (Figure 1.1) (Lee et al. 2012b).  
 
Neoplasia 
Demographics 
 ‘Pancreatic cancer’ as a categorical term encompasses a range of distinct 
pathologies with disparate origins and prognoses, including adenocarcinoma, acinar 
carcinoma, cystadenocarcinoma, endocrine carcinomas, and rarer forms such as poorly 
differentiated or undifferentiated carcinoma (Lack 1989). However, neoplasms of the 
exocrine pancreas are dominated by pancreatic ductal adenocarcinoma (PDAC), which 
accounts for approximately 85% of all cases (Alexakis et al. 2004). Accordingly, the term 
‘pancreatic cancer’ in general usage typically refers to PDAC, which is not only the most 
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common form of pancreatic cancer, but also the most deadly, with an average five-year 
survival rate of 6.7% (Howlader et al. 2014). It is typically discovered in patients over 40 
years old, with a median age at diagnosis of 71 (Howlader et al. 2014). Its prevalence in 
the US makes it the fourth-leading cause of cancer-related death in the country (Jemal et 
al. 2007). 
 Environmental and behavioral risk factors for pancreatic cancer are varied, and 
between 30 and 40% of all sporadic pancreatic cancer cases can be attributable to a 
known risk factor (Yeo 2015). Smoking (Maisonneuve and Lowenfels 2015), obesity 
(Eheman et al. 2012), diabetes (Liu et al. 2015), and pancreatitis (Lowenfels and 
Maisonneuve 2004) each significantly increase one’s risk of developing pancreatic 
cancer. Due to the general population prevalence of tobacco use, obesity and diabetes, 
more pancreatic cancer cases are attributable to these risk factors than to pancreatitis, 
even though pancreatitis, particularly when chronic, contributes far greater risk 
(Maisonneuve and Lowenfels 2015).  
Most pancreatic cancers are sporadic, but between 5 and 10% of all cases can be 
attributed to an inheritable predisposition (Murphy et al. 2002; Permuth-Wey and Egan 
2009). The most dangerous heritable conditions are Peutz-Jehgers syndrome and 
hereditary pancreatitis, which carry a 132-fold and 87-fold increased risk of pancreatic 
cancer, respectively (Rebours et al. 2008; Weiss 2014; Bruenderman and Martin 2015). 
Other heritable syndromes, including familial adenomatous multiple mole and melanoma, 
hereditary non-polyposis colon cancer, and hereditary breast and ovarian cancer 
syndromes, also carry significantly increased risk of pancreatic cancer over that of the 
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general population. Generally, the degree of additional risk is less than that for Peutz-
Jehgers and chronic pancreatitis (Becker et al. 2014; Bruenderman and Martin 2015). The 
genetic bases of many other familial pancreatic cancer syndromes, which do not track 
with known mutations, have yet to be elucidated (Rustgi 2014). For now, high-risk 
individuals with familial pancreatic cancer are the only ones receiving active screening 
for disease (Pandharipande et al. 2014; Urayama 2015), but efforts are being made to 
define high-risk populations without a family history of pancreatic cancer who would 
benefit from screening (Bruenderman and Martin 2015). Screening methods currently 
focus on endoscopic ultrasound as the diagnostic tool with the highest sensitivity and 
specificity, which may be supplemented by mutational profiling of cellular material from 
pancreatic secretions (Urayama 2015). 
 
Initiation and Progression 
 Early neoplastic lesions of the pancreas are called pancreatic intraepithelial 
neoplasias (PanINs) because they exhibit clear evidence of neoplastic change but they are 
restricted to the epithelial layer of the duct system (Distler et al. 2014). In oncology and 
cancer biology, it is the ability to invade across the basement membrane and into other 
tissues that defines malignant disease (Hanahan and Weinberg 2011). 
PanINs are graded based on cellular and histological criteria (Hruban et al. 2001). 
PanIN-1 lesions possess a tall columnar morphology with prominent supranuclear mucin, 
but their nuclei are normal in appearance and remain basally located (Figure 1.2) (Maitra 
and Hruban 2008). PanIN-2 lesions are defined by the presence of mild nuclear  
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abnormalities including loss of polarity, crowding, and hyperchromatism, and they may 
take on papillary or micropapillary architecture. PanIN-3 lesions, which can be 
considered ductal carcinoma in situ (DCIS), are characterized by elaboration of the 
epithelial layer into papillary or micropapillary architecture that may be stratified or 
exhibit cribriforming (the appearance of many small holes piercing a stratified 
epithelium, suggestive of ductal lumens). Cells in PanIN-3 lesions also have more 
advanced nuclear atypia than what is observed in PanIN-2, including aberrant mitoses, 
significant nuclear morphology defects, and prominent nucleoli. Luminal necrosis may 
occur as aggressive proliferation in situ forces cells away from the sustaining vascular 
beds of the surrounding stroma, and dystrophic goblet cells may also be present (Maitra 
and Hruban 2008). In the strictest usage, ‘PanIN’ refers to human lesions, whereas the 
separate term ‘mPanIN’ refers to lesions described in mice, although their pathological 
criteria are equivalent. 
PDAC is classically thought to arise from PanIN-3 lesions, but it can also evolve 
from other exocrine neoplasias, notably intraductal papillary mucinous neoplasms 
(IPMNs) and mucinous cystic neoplasms (MCNs) (Distler et al. 2014). IPMNs are 
typically solitary lesions of the larger pancreatic ducts in the pancreatic head, which can 
be visualized radiographically and are considered benign in the absence of an associated 
adenocarcinoma (Castellano-Megias et al. 2014). MCNs are also benign solitary lesions, 
but in contrast to IPMN are typically found in women and are localized to the pancreatic 
tail with an ovarian-type stroma (Fukushima and Zamboni 2014). Although initiating 
mutations can differ among PanIN, IPMN, and MCN (Saiki and Horii 2014), progression 
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to PDAC from any of these precursors typically involves mutations in TP53 and SMAD4 
(Yonezawa et al. 2008). Molecular biology and progression-related events in PDAC will 
be discussed in greater detail later on in this chapter. 
 
Detection, Staging, and Treatment 
 It is known that PanINs occur in the general population at much higher 
frequencies than pancreatic cancer (Singh and Maitra 2007). The implications of this are 
profound, since it suggests that although these lesions histologically anticipate the 
development of malignancy, there are many individuals who never progress to cancer 
despite having low-grade PanINs. This is very similar to the current situation with 
prostate cancer: most older men exhibit some degree of benign prostatic hyperplasia 
(BPH), which is the precursor to prostate cancer, but most of those men will not progress 
to invasive disease, and a biomarker commonly used to stage prostate cancer is also 
produced by BPH, further complicating diagnosis (Canto et al. 2003). Similarly, any 
effective screening modality for PanINs would have to be sensitive and highly specific 
for the rarer PanIN-2 and PanIN-3 lesions, rather than the highly prevalent PanIN-1 
lesions. Thus far, very few studies have identified candidate gene signatures of advanced 
PanINs with potential as biomarkers (Pan et al. 2009; Yi et al. 2013). This is partially due 
to the difficult and expensive nature of proteomics, and recent advances in RNA biology 
have resulted in a shift towards a search for microRNA biomarkers, which can be easily 
profiled in a relatively inexpensive and high-throughput manner (Xue et al. 2013).  
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Considering the difficulties involved in detecting and discriminating PanIN 
lesions, the detection of mature pancreatic cancer in its earliest non-invasive stages is the 
highest priority. Currently the only potentially curative treatment for pancreatic cancer is 
surgical removal of localized disease. ‘Localized’ describes the fact that the tumor has 
not extended beyond the pancreas and has not metastasized to regional lymph nodes or 
more distant sites. Just 9% of all patients diagnosed with pancreatic cancer are localized 
at the time of diagnosis (Howlader et al. 2014). These patients are candidates for a radical 
surgery: a pancreaticoduodenectomy, or ‘Whipple,’ as it is often called in the US, 
memorializing the American surgeon who refined it in the 1930’s. The surgery is quite 
drastic, removing the distal portion of the stomach, most of the duodenum, the head of 
the pancreas, the common bile duct and the gall bladder. This subsequently requires re-
anastomosing of the remaining third of the duodenum to the proximal stomach, the tail of 
the pancreas, and the remaining portion of the bile duct. The procedure involves the 
dissection of numerous blood vessels which can be the source of life-threatening blood 
loss. If patients survive the surgery, then they experience the best possible prognosis for 
one who has been diagnosed with pancreatic cancer: a 25.8% chance at a five-year 
survival (Howlader et al. 2014). They spend this time adapting to insulin-dependent 
diabetes and chronic maldigestion, requiring exogenous insulin and supplementary 
pancreatic enzymes (Lindkvist 2013). Once their surgical wounds have healed, patients 
may undergo adjuvant chemotherapy to improve their chances of long-term survival. 
Treatment with the chemotherapeutic drug gemcitabine in this setting can extend median 
survival by approximately six months (Oettle et al. 2013). 
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Most patients with radiographically localized disease will undergo surgery, but in 
many cases, open surgery will reveal that the tumor has invaded adjacent structures, or 
pathological analysis of regional lymph nodes obtained during the resection will reveal 
disseminated disease. These patients with ‘regional’ disease comprise 28% of all 
pancreas cancer patients, and their five-year survival rate is 10% (Howlader et al. 2014). 
If staging is properly upgraded in the operating room prior to the full commencement of 
the Whipple, then the surgery may be aborted. However, due to the complex anatomical 
nature of the pancreas’ location in the abdominal cavity, and the aggressive potential of 
the tumors to progress in the short time between imaging and surgery, surgeons may not 
visualize or anticipate regionally advanced disease until the procedure is well under way. 
In my personal experience observing a Whipple here at the University, this occurred 
approximately eleven hours into surgery when the stomach and duodenum had been 
bisected and most major vessels to the pancreas had been ligated. It then became apparent 
that the tumor was invasive to the aorta, ruling out the possibility of clean surgical 
margins. Recent efforts have pursued pre-surgical treatments to downstage regional 
disease or preserve localized status until surgery can be performed. Such ‘neoadjuvant’ 
therapies show great promise and are improving outcomes (Rajagopalan et al. 2013; 
Ansari et al. 2014; Mellon et al. 2015). 
For the 53% of pancreas cancer patients who present with widely metastatic 
disease at diagnosis, surgery is not an option, and these patients have an appalling 2.3% 
chance of surviving for five years (Siegel et al. 2015). This is simultaneously the most 
dismal and the most common occurrence. Standard of care for these patients is a 
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chemotherapeutic regimen that has evolved from the original anti-pancreatic-cancer 
drugs, 5-fluorouracil (5-FU) and gemcitabine. 
5-FU and gemcitabine are nucleoside analogs that incorporate into the RNA and 
DNA of dividing cells, respectively, disrupting protein translation and arresting DNA 
synthesis, leading to cell death (Wilkinson et al. 1975; Plunkett et al. 1995). 5-FU was 
used for several decades as the standard of care for patients prior to the creation of 
gemcitabine (Arbuck 1990). Initial studies evaluating the benefit of gemcitabine versus 5-
FU found only a one-month improvement in median survival, but a higher percentage of 
patients on gemcitabine reported improved pain symptoms compared to those receiving 
5-FU (23.8% vs. 4.8%) (Burris et al. 1997). Since this study, oncologists have attempted 
to develop improved drug regimens using gemcitabine as the core therapeutic and 
standard of care. The best currently available treatment is a cocktail of oxaliplatin, 
irinotecan, leucovorin, and 5-FU in combination with gemcitabine. This regimen, called 
FOLFIRINOX, provides a median survival benefit of 4.3 months over gemcitabine alone, 
typically with three months of progression-free survival (Conroy et al. 2011). However, 
this regimen carries increased toxicity compared to gemcitabine, with higher rates of 
severe adverse events including neutropenia, thrombocytopenia, diarrhea, and neuropathy 
(Conroy et al. 2011). Ongoing work is being done to tailor the dosing of FOLFIRINOX 
to find efficacious schedules that will reduce toxicity, and thereby increase the number of 
patients who can tolerate this treatment (Gunturu et al. 2013), and for now FOLFIRINOX 
is considered standard of care for patients with advanced pancreatic cancer. Therefore, in 
the two decades since we began using gemcitabine to treat pancreatic cancer, we’ve been 
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able to provide the average patient with an additional four months of life. This stalemate 
has spurred basic biologists to explore the molecular biology of PDAC in the hopes of 
identifying druggable weaknesses in this nearly untreatable disease. 
 
Molecular Biology 
The greatest unifying pattern of pancreatic cancer is the mutational activation of 
KRAS (Almoguera et al. 1988; Smit et al. 1988). It is observed in the earliest PanINs (Shi 
et al. 2009; Kanda et al. 2012) and its expression is maintained late in disease progression 
(Biankin et al. 2012). Pancreatic cancers with activated KRAS exhibit oncogene 
addiction, whereby suppression of KRAS activity induces tumor cell death and regression 
of PanINs back to normal tissue (Collins et al. 2012a; Collins et al. 2012b; Ying et al. 
2012). Understanding KRAS is an essential prerequisite to an understanding of pancreatic 
cancer. 
KRAS is a member of a larger family of RAS proteins, including HRAS and 
NRAS, which are responsible for relaying and amplifying signals from growth factor 
receptors at the cell surface (Cox and Der 2010). Signaling through RAS begins when 
growth factors, such as EGF, bind to their transmembrane receptors, triggering their 
dimerization and the phosphorylation of their cytoplasmic tails. These phosphorylated 
sites can then recruit growth-factor-receptor-bound protein 2 (GRB2) to the plasma 
membrane by interacting with its SH2 domain. GRB2 in turn recruits Son-of-Sevenless 
(SOS), which activates RAS by facilitating RAS binding to GTP. 
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Figure 1.3. RAS signaling is controlled by GAPs and GEFs. 
This abbreviated schematic shows some of the pathways activated by RAS proteins and is not 
exhaustive. Mutations commonly associated with pancreatic cancer (e.g. KRAS
G12D
) affect RAS’ 
association with GAPs. All downstream signaling from RAS occurs only in the GTP-bound ‘on’ state. 
Downstream pathways generate overlapping and distinct effects in pancreatic cancer, and are subject 
to regulation at multiple steps. DUSP: dual-specificity phosphatase. 
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RAS proteins cycle through active and inactive conformational states by their 
association with GTP and GDP, respectively (Figure 1.3) (Scolnick et al. 1979; 
Schlichting et al. 1990; Cox and Der 2010). This cycling is governed by the hydrolysis of 
RAS-bound GTP to GDP, and the exchange of GDP for fresh GTP. The hydrolysis of 
GTP to GDP is catalyzed by RAS itself and is accelerated by the binding of GTPase 
activating proteins (GAPs) (Vigil et al. 2010). The exchange of GDP for GTP is 
facilitated by a family of proteins that includes SOS, called guanidine nucleotide 
exchange factors (GEFs). GDP-bound RAS is unable to recruit and activate downstream 
effectors, and in the course of normal cellular signaling, RAS proteins spend most of their 
time in a GDP-bound ‘off’ state with only intermittent pulses of GTP-induced activity.  
Importantly, the auto-inactivating GTPase reaction of an isolated RAS molecule is very 
slow (Chung et al. 1993), and cells therefore rely heavily on the activity of GAPs for the 
proper inactivation of RAS signaling.  
Relevant to the balance in RAS’ interaction with GAPs and GEFs is the fact that 
RAS is normally restricted to endomembranes by farnesylation of its C-terminus (Casey 
et al. 1989; Fehrenbacher et al. 2009). This localization brings RAS in close proximity to 
its activating GEFs and is required for RAS activity (Kohl et al. 1993). KRAS can 
generate two protein products through alternative splicing: KRAS4A and KRAS4B. 
KRAS4A, like the other members of the RAS family, HRAS and NRAS, is additionally 
modified for membrane association by palmitoylation (Laude and Prior 2008). KRAS4B, 
however, lacks the upstream amino acid signals required for palmitoylation, and therefore 
has a more dynamic interaction with the plasma membrane (Silvius et al. 2006). There is 
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evidence from studies of HRAS and NRAS that depalmitoylation can occur and drive 
rapid redistribution away from membranes, thereby inactivating RAS signaling, but the 
relevance of this regulation to the activity of KRAS4A remains unclear (Ahearn et al. 
2012). RAS proteins can also be post-translationally modified by phosphorylation, mono- 
and di-ubiquitination, and S-nitrosylation, although the specific impact of these 
alterations are largely uncharacterized (Ahearn et al. 2012). 
 There are many downstream pathways that are activated by KRAS in a GTP-
dependent manner (Figure 1.3) (Cox and Der 2010). One of the first identified 
downstream effectors of KRAS signaling was the RAF/MEK/ERK pathway (Dickson et 
al. 1992; Moodie et al. 1993). This signaling cascade results in the activation of 
transcription factors including c-JUN, FOS, and ELK1 to drive cell cycle progression 
(Downward 2003). KRAS also stimulates PI3K to activate AKT (Marte and Downward 
1997) and PDK1 (Eser et al. 2013; Ferro and Falasca 2014). These pathways relay pro-
survival and proliferative signals through yet other effectors including mammalian target 
of rapamycin (mTOR), Cyclin D1, and HIF-1α (Bauer et al. 2015). Independent of PI3K, 
RAS proteins can signal through TIAM to drive RAC1 activation and promote 
cytoskeletal rearrangement (Lambert et al. 2002). Another major pathway known to be 
activated by RAS is the phospholipase C-epsilon (PLCε) signaling pathway, which 
activates protein kinase C (PKC) to modulate cytoskeletal activity (Kelley et al. 2001) 
Mutational activation of KRAS in cancer typically entails a missense mutation at 
codon 12 or 13, substituting wild-type glycine residues for a more bulky aspartate or 
valine (e.g. KRASG12D or KRASG12V) (Capon et al. 1983). These mutations render KRAS 
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incapable of effectively binding to the GAPs that normally arrest KRAS signaling, 
resulting in aberrantly stable activation of downstream pathways (Scheffzek et al. 1997). 
The far less common mutation at codon 61 of a glutamine (e.g. KRASQ61L or KRASQ61H; 
Prior et al, Cancer Res 2012) achieves a similar end by destroying a critical residue in the 
active site of KRAS’ GTPase domain (Figure 1.3). Mouse models indicate, however, that 
mutational activation of KRAS is not sufficient to drive carcinogenesis, and some 
component of inflammation must be present to drive progression (Guerra et al. 2007; 
Guerra et al. 2011; Daniluk et al. 2012; Zhang et al. 2013). Moreover, EGFR signaling is 
required for the full oncogenic effect of KRASG12D (Ardito et al. 2012; Navas et al. 
2012), as is signaling downstream of the IGF1 receptor (Appleman et al. 2012), 
emphasizing that although mutational activation of KRAS is a very early event, its 
primary function appears to be to amplify or deregulate cellular responses to extracellular 
stimuli. This broadens the possibilities of therapeutic intervention against KRAS-mutant 
cancers to include upstream signaling components. 
Excessive activation of growth factor signaling in normal cells induces oncogene-
induced senescence (OIS), which is a physiological response that forms one of the first 
lines of defense against neoplasia. Senescence is characterized by an irreversible exit 
from the cell cycle, and in the particular case of OIS, is driven by upregulation of the 
CDKN1A and CDKN2A genes (Larsson 2011). The tumor suppressor gene CDKN2A 
encodes two protein products by an alternative splicing mechanism: the cell cycle 
inhibitor P16INK4A and the MDM2 antagonist P14ARF (Quelle et al. 1995). INK4A is a 
cyclin-dependent kinase inhibitor that blocks the G1-S transition, and ARF drives 
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proteolysis of the TP53 antagonist MDM2, thereby driving TP53 accumulation and cell 
cycle arrest in G1 and G2 (Zhang et al. 1998). Senescence is observable in PanIN-1 
lesions, where activation of KRAS is the primary driver, but telomere shortening and 
accrual of DNA damage are also present and contribute to the induction of senescence in 
a TP53-P21-dependent manner (Hruban et al. 2008). This occurs via the ATM/ATR-
TP53-P21WAF1 cascade that detects DNA damage (Larsson 2011). Thus progression 
beyond PanIN-1 requires the inactivation of key tumor suppressors in order to bypass 
OIS. Indeed, disruption of CDKN2A function is commonly observed in PanIN-2 lesions 
(Hruban et al. 2008), and in over 95% of PDAC tumors, where INK4A and ARF function 
can both be lost (Caldas et al. 1994; Bardeesy et al. 2006a). This single mutation 
therefore attenuates two tumor suppressive responses to OIS by simultaneously deleting 
INK4A to allow cell cycle progression and deleting ARF to desensitize cells to DNA 
damage. 
TP53 disruption is also observed in late PanINs and over 75% of PDAC cases, 
and is thought to contribute greatly to the genomic instability of PDAC by promoting 
DNA damage (Halazonetis et al. 2008; Jones et al. 2008; Koorstra et al. 2009). 
Interestingly, TP53 is not normally completely lost in PDAC, as one allele may be 
deleted, but the remaining allele is typically disrupted by missense mutation (Redston et 
al. 1994), suggesting a gain-of-function activity for TP53 in these tumors. 
Genetic disruptions of the TGF-β effector SMAD4 are seen in over 50% of PDAC 
cases, which allows bypass of TGF-β-induced growth arrest (Hahn et al. 1996; Iacobuzio-
Donahue et al. 2004). Mouse modeling has demonstrated that loss of SMAD4 definitively 
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enhances PanIN progression to PDAC; but in a subset of tumors, intact SMAD4 can 
promote growth, supporting the clinical evidence that SMAD4 loss is not universally 
required for tumor progression (Bardeesy et al. 2006b). In the absence of SMAD4, TGF-
β signaling plays a role in the activation of RAS to drive tumor progression (Xia et al. 
2015). 
 
microRNAs 
Nature, Pathway, and Mechanism 
 microRNAs (miRNAs) are a class of short RNA molecules initially discovered 
and described as the non-coding RNA product of the C. elegans gene lin-4 (Lee et al. 
1993; Wightman et al. 1993). Since then, miRNAs have come to be appreciated as highly 
diversified molecules that are broadly conserved across species (Lagos-Quintana et al. 
2001; Lau et al. 2001; Lee and Ambros 2001). They play roles in development, normal 
physiology and disease (Schickel et al. 2008; Sayed and Abdellatif 2011; Vidigal and 
Ventura 2015), and are predicted to control the expression of over half of the human 
transcriptome (Bartel 2009; Friedman et al. 2009). Our evolving understanding of 
miRNA processing and activity has been extensively reviewed (Filipowicz et al. 2008; 
Davis and Hata 2009; Newman and Hammond 2010; Huntzinger and Izaurralde 2011; 
Braun et al. 2012; Blahna and Hata 2013; Olive et al. 2015). Graphical representation of 
the miRNA biogenesis pathway about to be discussed is summarized in Figure 1.4 (Hata 
and Lieberman 2015). 
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miRNAs are initially transcribed as primary, or ‘pri-miRNAs,’ which possess a 
stereotypical stem-loop structure (aka hairpin) within the context of a longer, single-
stranded RNA transcript (Lee et al. 2002). This hairpin is recognized by the 
microprocessor complex, key components of which are the RNase III enzyme DROSHA 
(Lee et al. 2003) and its partner DiGeorge syndrome critical region 8 (DGCR8) (Denli et 
al. 2004; Gregory et al. 2004; Han et al. 2004; Landthaler et al. 2004). The 
microprocessor cleaves the pri-miRNA near the base of the stem to release a free hairpin, 
now a ‘pre-miRNA.’ This is then exported from the nucleus by Exportin 5 (XPO5) for 
further processing in the cytosol (Yi et al. 2003). Notably, some miRNAs can arise from 
within introns through splicing and debranching reactions that bypass the need for 
microprocessor cleavage (Okamura et al. 2007; Ruby et al. 2007; Yang and Lai 2011). 
Once in the cytosol, pre-miRNAs are bound by another RNase III enzyme, 
DICER. DICER, in association with trans-activation response RNA-binding protein 
(TRBP) (Chendrimada et al. 2005; Haase et al. 2005) or protein activator of PKR (PACT)  
(Lee et al. 2006), cleaves off the terminal loop of the pre-miRNA to generate a double-
stranded product around 22 nucleotides in length with small 3’ overhangs (Bernstein et 
al. 2001; Grishok et al. 2001; Hutvagner et al. 2001; Ketting et al. 2001). TRBP and 
PACT are not strictly necessary for pre-miRNA processing by DICER, but they do play a 
role in modulating the position of DICER cleavage within the pre-miRNA, which alters 
the activity of the mature miRNA (Fukunaga et al. 2012; Lee et al. 2013). 
The DICER-bound double-stranded RNA intermediate (dsRNA) now consists of 
the mature miRNA and its complementary strand (miRNA and miRNA*, respectively). 
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The transfer of one strand to Argonaute family proteins (AGO) to act as the mature 
miRNA is influenced by a number of factors including the thermodynamic stability of the 
RNA strands and Dicer complex association with TRBP or PACT, select one strand 
(Khvorova et al. 2003; Matranga et al. 2005). The complementary strand is then degraded 
by AGO’s RNase activity. Mammals possess four AGO family proteins (AGO1-4) but 
catalytic activity appears to be restricted to AGO2 (Hutvagner and Simard 2008). The 
AGO2-miRNA complex is called the miRNA-induced silencing complex (miRISC) and 
is now capable of screening mRNA transcripts for complementary sequences and 
catalyzing post-transcriptional gene suppression (herein ‘translational repression’), 
through mechanisms that may or may not involve mRNA degradation.  
The precise mechanisms of miRISC-induced translational repression, and the 
cofactors involved, remain an area of intense investigation. The earliest descriptions of 
miRNA function demonstrated that mRNA decay was not required for translational 
repression (Olsen and Ambros 1999; Seggerson et al. 2002). Since then, it has been 
shown that miRNAs can repress translation in active polysomes by inhibiting 
translational initiation or promoting ribosomal drop-off during peptide elongation 
(Humphreys et al. 2005; Pillai et al. 2005; Maroney et al. 2006; Nottrott et al. 2006; 
Petersen et al. 2006; Kiriakidou et al. 2007). Although not required for translational 
repression, mRNA degradation does also occur through decapping and deadenylation of 
the targeted mRNA (Behm-Ansmant et al. 2006; Giraldez et al. 2006; Wu et al. 2006; Wu 
et al. 2010; Chekulaeva et al. 2011; Fabian et al. 2011) via the recruitment of additional 
factors to the miRISC complex (Huntzinger and Izaurralde 2011). 
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AGO2 is the critical component of miRISC (Hammond et al. 2001), and it 
possesses the ability to cleave mRNA transcripts (Pillai et al. 2005). Direct mRNA 
cleavage in mammals by AGO2’s ‘slicer’ activity typically requires complete sequence 
complementarity, as in the maturation and activity of small interfering and short hairpin 
RNAs1 (siRNAs and shRNAs) (Wang et al. 2009). While mRNA cleavage has been well-
described in plants and flies (Carbonell et al. 2012), it is less prominent in mammals, 
possibly due to differences in the kinetics of mammalian AGO2 catalytic activity (Wee et 
al. 2012). Slicer-independent translational repression involving partial sequence 
complementarity is vastly more common in the normal activity of mammalian miRNAs, 
and it is responsible for much of the off-target effects of engineered siRNAs and shRNAs 
(Jackson et al. 2003; Jackson et al. 2006). Translational repression in the context of 
partial complementarity depends greatly on the miRNA seed sequence, which consists of 
nucleotides 2-7 in the 5’ end of the mature miRNA (Lewis et al. 2003b). The contribution 
of miRNA-mRNA binding events to target selection will be discussed in greater in a later 
section. 
There are two intriguing findings that bear mention for their inconsistency with 
the bulk of the published literature regarding miRNAs. One study found that target gene 
upregulation occurred as a result of miRNA binding to the mRNA transcript, but this 
activity appeared restricted to quiescent cells (Vasudevan et al. 2007). A more recent 
                                                 
1 siRNAs are double-stranded RNAs delivered transiently into cells that are capable of gene suppression 
(Fire et al. 1998; Hammond et al. 2000) through their ability to be recognized by DICER and loaded into 
miRISC. shRNAs are single-stranded precursors with the conserved stem-loop secondary structure 
common to pre-miRNAs, which makes them more efficient substrates for DICER processing (Siolas et al. 
2005). They can be synthesized and introduced directly for short-term processing and activity, or they may 
be expressed from a transgene for long-term gene suppression (Paddison et al. 2002) 
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supporting observation has demonstrated miRNA-dependent gene upregulation in a 
cancer context, where miR-483 bound to the 5’UTR of actively transcribing IGF2 to 
recruit factors and promote transcription (Liu et al. 2013). Another interesting 
observation that expands the possibilities of normal miRNA activity is that miR-451 can 
evidently be processed from pre-miRNA to mature and functional miR-451 through a 
DICER-independent pathway that requires the slicer activity of AGO2 (Cheloufi et al. 
2010; Cifuentes et al. 2010). To date, no other miRNAs have yet been identified that can 
be processed in this manner. 
 
Regulation of microRNA Activity 
As pervasive regulators of gene expression, miRNAs are themselves subject to 
many layers of regulation across all levels of their biogenesis and activity. At this early 
stage in our understanding, the data suggests a daunting diversity and complexity of 
regulatory mechanisms, but even a superficial understanding of normal miRNA 
regulation greatly informs our understanding of how it can be deregulated in cancer. 
Much of what is discussed below is graphically depicted in Figures 1.4 and 1.5 (Hata and 
Lieberman 2015; Olive et al. 2015). 
 The microprocessor complex is a major hub of regulatory activity in the 
biogenesis of miRNAs. The association of DEAD-box RNA helicase p68 (DDX5 or p68) 
and DEAD-box RNA helicase p72 (DDX17 or p72) with the microprocessor creates the 
‘super microprocessor,’ and their binding regulates the expression of different subsets of 
miRNAs (Slezak-Prochazka et al. 2010; Fuller-Pace and Moore 2011). For example, it is  
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Figure 1.5. Mechanisms regulating miRNA biogenesis. 
A more exhaustive representation of the modulatory mechanisms of miRNA biogenesis is presented. 
Blue boxes are stimulatory effects, whereas red boxes are inhibitory. Listed miRNAs are those that 
are known to be particularly affected by each factor. Figure is reproduced from: V. Olive, A. 
C. Minella, and L. He, Outside the coding genome, mammalian microRNAs confer structural and 
functional complexity. Sci. Signal. 8, re2 (2015), reprinted with permission from AAAS. 
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known that ligand-specific SMADs can bind to DDX5 and enhance the processing of 
some miRNAs (Davis et al. 2008). Similar DDX5 binding activity has been observed for 
TP53 in its promotion of several tumor-suppressive miRNAs upon DNA damage (Suzuki 
et al. 2009). These studies suggest that transcription factors may play transcription-
independent roles in regulating miRNA biogenesis. Furthermore, it has been shown that 
BRCA1 can recognize the secondary structure of some pri-miRNAs directly and recruit 
the microprocessor through its association with TP53, SMAD3, and DDX5 (Kawai and 
Amano 2012). In a conceptually similar model, nuclear YAP dissociates DDX17 from 
the microprocessor to impair the expression of DDX17-facilitated miRNAs, thereby 
linking cellular confluency to miRNA expression (Mori et al. 2014).  
Regulation of microprocessor activity also occurs through binding of other factors 
to pri-miRNAs, which can enhance or suppress processing. Enhancement can occur 
through protein binding to conserved regions in the terminal loops of pri-miRNAs, 
resulting in relaxation of the pri-miRNA stem to provide more favorable DROSHA 
cleavage (Michlewski et al. 2008). This has been described for HNRNPA1, which binds 
to the terminal loop of pri-miR-18a in a sequence-dependent manner and is required for 
the processing of this miRNA (Guil and Caceres 2007). KH-type splicing regulatory 
protein (KSRP) also promotes the processing of a subset of miRNAs, including let-7, 
miR-20a and miR-21, by binding to their pri- and pre-miRNA terminal loops and 
recruiting DROSHA and DICER complexes (Trabucchi et al. 2009). Suppression of 
processing can also occur, as in the case of let-7’s regulation by LIN28, where terminal 
loop binding of LIN28 inhibits microprocessor recruitment (Newman et al. 2008; 
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Viswanathan et al. 2008). Nuclear Factor-90 (NF90) and NF-45 also bind the terminal 
loops of pri-miRNAs and are negative regulators of processing (Sakamoto et al. 2009). 
Furthermore, HNRNPA1, previously described as a processing enhancer, has been shown 
to suppress processing of pri-let-7 by displacing KSRP from the terminal loop 
(Michlewski and Caceres 2010). This study illustrates the importance of cellular context 
and balance for the net activity of these factors. 
Cytosolic regulation of miRNA processing can occur in a miRNA-specific 
manner. A particularly well-studied example of this is the relationship between the 
miRNA let-7 and its regulator LIN28. In addition to its role in the nucleus regulating pri-
miRNA processing, LIN28 also binds to the terminal loop of pre-let-7 in the cytoplasm 
and inhibits its processing by DICER (Heo et al. 2008; Rybak et al. 2008). This occurs 
via the recruitment of terminal uridylyl transferase 4 (TUT4), which uridylates the 3’ end 
of the pre-miRNA, thereby preventing DICER binding and targeting the pre-miRNA for 
degradation (Heo et al. 2009). Uridylation has since been observed to occur across a 
broad range of pre-miRNAs (Ple et al. 2012; Westholm et al. 2012). TUT4 has been 
implicated in the regulation of other pre-miRNAs besides let-7 (Jones et al. 2012), and 
the related protein TUT7 has been shown to regulate a similar subset of pre-miRNAs 
(Thornton et al. 2014), but other protein factors involved in pre-miRNA uridylation have 
yet to be described. Opposing uridylation, adenylation of the 3’ end of mature miRNAs 
by poly-A polymerases promotes stability (Katoh et al. 2009), but the mechanisms of 
poly-A polymerase recruitment to miRNAs remains unknown. 
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AGO2 and DICER activity can also be modulated by cellular pathways to create 
broad effects on miRNA processing. AGO2 and DICER levels can be suppressed through 
selective autophagy (Gibbings et al. 2012), and DICER is itself regulated by miRNAs 
(Martello et al. 2010), including the tumor-suppressive miRNA let-7 (Jakymiw et al. 
2010). Numerous phosphorylation events integrate growth and stress signals to exert 
additional control over the output of the miRNA pathway. It is known that AGO2 is 
phosphorylated downstream of RAS signaling and that this is a reversible process critical 
to the gene silencing that occurs in OIS (Yang et al. 2014). AGO2 phosphorylation has 
been shown to occur in a MAPK- (Zeng et al. 2008) and AKT3-dependent manner 
(Horman et al. 2013), although additional effectors downstream of RAS likely contribute. 
Phosphorylation of AGO2 on serine387 is required for translocation of AGO2-bound 
mRNAs to processing bodies (P Bodies) (Zeng et al. 2008), where translational 
suppression occurs via inhibition of translational initiation and eventual mRNA 
destabilization. Also, phosphorylation of TRBP via the ERK pathway promotes DICER-
mediated processing of many miRNAs as an effector of RAS signaling (Paroo et al. 
2009), although in this study let-7 was specifically suppressed by activated TRBP via an 
unknown mechanism.  
Very recently, a class of RNA molecules has been identified, called competing 
endogenous RNA (ceRNA). These RNAs encode miRNA binding sites that allow them 
to act as decoy transcripts and alleviate miRNA suppression of a particular mRNAs (Tan 
and Marques 2014). A key determinant of whether an RNA will behave as a ceRNA 
appears to be the relative expression ratios of the miRNA, the target mRNA, and the 
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ceRNA (Bosson et al. 2014), such that very highly expressed mRNAs or miRNAs are not 
likely to be subject to significant regulation by ceRNAs. One prominent example of 
ceRNA biology that has garnered a lot of attention is the recently discovered activity of 
the PTEN pseudogene, PTENP1. PTENP1 acts as a ceRNA for PTEN, such that 
expression of PTENP1 increases expression of PTEN by alleviating miR-21-mediated 
suppression of the coding transcript (Yu et al. 2014). This is a strikingly elegant example 
of a previously unappreciated role for pseudogene transcripts in miRNA-mediated gene 
regulation. However, ceRNAs have since grown as a concept to include protein-coding 
transcripts as well, such that now the field is faced with the prospect of interpreting the 
interrelationships of all mRNAs within a miRNA targetome to define mRNA-ceRNA 
relationships (Poliseno and Pandolfi 2015). The feasibility of such a daunting analysis 
remains to be seen. 
 
Methods of Target Prediction and Validation 
 Because miRNAs exert their effects in a sequence-specific manner, significant 
effort has been put to devising methods of predicting functional miRNA targets. 
Predictive algorithms have predominantly evolved from the idea that canonical miRNA 
binding sites (binding to positions 2-7, or ‘6mer’ sites) have a stronger effect on mRNA 
expression than binding to other regions of the miRNA (Lim et al. 2005). Target 
prediction methods also typically take into account that binding to position 8 in the 
miRNA (7mer-m8), or the presence of an adenine nucleotide in the mRNA across from 
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position 1 in the miRNA (7mer-A1), or both of these conditions together (8mer) enhance 
translational repression (Grimson et al. 2007; Nielsen et al. 2007). 
One of the first available tools for predicting miRNA targets was TargetScan 
(Friedman et al. 2009). This platform leveraged 3’UTR conservation across more than 20 
species to develop probability scores for predicted miRNA targets: a strong predicted 
miRNA target is one with a conserved canonical miRNA binding site within a poorly 
conserved 3’UTR, whereas highly conserved 3’UTRs may contain conserved miRNA 
sites, but these may be conserved for reasons unrelated to miRNA activity and therefore 
receive a lower score. Friedman and colleagues also confirmed that binding sites for the 
‘offset 6mer’ (binding to miRNA positions 3-8) were significantly conserved in 
mammalian 3’UTRs, although the overall descending order of conservation proceeded as 
8mer > 7mer-m8 > 7mer-A1 > 6mer > offset 6mer (Friedman et al. 2009). Furthermore, 
their model included estimates of conservation allowing for G:U wobble in the 5’ end of 
the miRNA (Doench and Sharp 2004), as well as bulges and compensatory binding in the 
3’ end of the miRNA at nucleotides 13-16 (Brennecke et al. 2005). Thus, a TargetScan 
context score for a particular mRNA incorporates miRNA binding site conservation, 
3’UTR conservation, predicted suppression activity based on the type of seed match, the 
background conservation for that type of seed match, and the number of seed matches in 
the transcriptome for that particular miRNA (Friedman et al. 2009). 
Numerous other tools have been developed to predict miRNA targets in addition 
to TargetScan (John et al. 2004; Krek et al. 2005; Miranda et al. 2006; Maragkakis et al. 
2009), but they produce widely different target sets for the same miRNA, depending on 
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how various factors are weighed in each algorithm (Min and Yoon 2010; Thomson et al. 
2011). Furthermore, not enough is known about the biology of unusual miRNA binding 
sites to allow accurate predictions, including the predominantly 3’ pairing seen between 
miR-92 and its targets (Helwak Cell 2013), and so-called ‘centered pairing’ (Shin et al. 
2010). Moreover, although miRNA target sites preferentially occur at the start and end of 
long 3’UTRs (Gaidatzis et al. 2007), it has been shown that miRNAs can also bind to 
coding regions of mRNA transcripts (Tay et al. 2008; Rigoutsos 2009). Such sites are 
effective in translational suppression but are less effective than 3’UTR sites at mRNA 
destabilization (Fang and Rajewsky 2011; Reczko et al. 2012; Hausser et al. 2013). 
Further complicating efficacy prediction, local A/U content of the 3’UTR is known to 
promote destabilization of the transcript (Jing et al. 2005; Hausser et al. 2009).  
More definitive strategies for the identification of miRNA targets rely on the 
experimental validation of binding events, although even these strategies are limited by 
fixation steps that cannot capture the dynamic nature of binding reactions. High-
throughput sequencing of RNA that has been cross-linked to AGO2 protein (AGO2 
HITS-CLIP) offers the ability of knowing RNA sequences bound to AGO2 at the time of 
fixation, but the true miRNA-mRNA binding relationships can be difficult to determine 
and must be partly inferred with bioinformatics (Chi et al. 2009). A more direct approach 
involves the crosslinking, ligation, and sequencing of miRNA-mRNA hybrids (CLASH), 
which preserves the miRNA and its cognate binding site in one coherent read (Helwak et 
al. 2013), but it reports large numbers of noncanonical binding sites and has poor 
predictive value of the strength of miRNA function at an observed site. A more recent 
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advance is the use of biotinylated, psoralen-containing pre-miRNA mimics that 
purportedly improves capture frequency of binding sites (Imig and Brunschweiger 2015), 
although it still cannot predict the repressive strength of a given interaction. 
Proteomics ultimately offers the most powerful means of determining true 
relationships between miRNAs and net gene expression. Stable isotope labeling with 
amino acids in cell culture (SILAC) combined with mass spectroscopy offers a means to 
measuring acute changes in protein expression caused by miRNAs (Baek et al. 2008; 
Selbach et al. 2008). Combining SILAC with target prediction algorithms or HITS-CLIP 
approaches presents the greatest chance of experimentally identifying true miRNA targets 
in an unbiased way. 
 
The microRNA Pathway in Cancer 
 Soon after their discovery, miRNAs gained attention as regulators of cancer 
biology, and the earliest miRNAs to be studied in this context were let-7, miR-21, and the 
miRNAs of the mir-17~92 cluster (Takamizawa et al. 2004; Chan et al. 2005; Hayashita 
et al. 2005). Since then, an explosion of work has begun to characterize the many 
context-specific activities of miRNAs in cancer. Due to the evolutionary complexity of 
cancer, there exist near limitless possibilities in the ways a tumor may alter miRNA 
biogenesis in its favor, and just a few of those mechanisms will be discussed here, along 
with some of the more well-described oncogenic and tumor-suppressive miRNAs. 
 Oncogenes and tumor suppressors involved in cancer initiation and progression 
are known to alter miRNA expression. It has been shown that AGO2 phosphorylation by 
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EGFR causes deficits in the processing of a particular subset of miRNAs  (Shen et al. 
2013). This can occur downstream of RAS signaling in a MAPK and AKT-dependent 
manner, which has profound implications in the cancer context where these pathways are 
aberrantly activated (Zeng et al. 2008; Horman et al. 2013).  EGF has been shown to 
upregulate a pro-metastatic subset of miRNAs in mammary cells , and ERK activation 
can also increase TRBP phosphorylation to promote DICER-mediated processing of 
many miRNAs, which again places miRNA biogenesis downstream of RAS signaling 
(Paroo et al. 2009). Much of the work regarding oncogene control of miRNA processing 
is fairly recent and has not received as much attention as the characterization of 
individual miRNAs that themselves play the part of tumor-suppressors or oncogenes. 
 Let-7 is now a well-established tumor suppressor whose expression is reduced in 
many cancers (Takamizawa et al. 2004; Zhang et al. 2014b). Overexpression of let-7 in 
cancer cells can revert EMT phenotypes and trigger cell cycle arrest and cell death 
(Kumar et al. 2008; Li et al. 2009). Reduced let-7 expression is thought to be selected for 
during tumor progression because of its ability to suppress key oncogenes, including 
RAS family proteins, MYC, and high-mobility group A protein 2 (HMGA2) (Johnson et 
al. 2005; Lee and Dutta 2007; Mayr et al. 2007; Sampson et al. 2007). HMGA2 is a non-
histone chromatin factor whose expression is often upregulated in cancer, leading to an 
invasive phenotype (Watanabe et al. 2009). HMGA2 is normally regulated by let-7, and 
overexpression of HMGA2 can occur as a result of a shortened 3’UTR that omits these 
let-7 binding sites (Klemke et al. 2010; He et al. 2014b).  
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Figure 1.6. The mir-17~92 cluster and its related paralogs encode members of four miRNA 
families. 
miRNAs sharing the same seed sequence are grouped by color. Not all clusters contain miRNAs from 
all four families: notably, mir-106b~25 encodes only miR-17 and miR-92 families. 
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miR-21 is an equally well-established oncogene that is overexpressed in most 
tumor types (Chan et al. 2005; Volinia et al. 2006; Si et al. 2007; Schetter et al. 2008). It 
has been shown to suppress the expression of several key tumor suppressors, including 
PTEN, PDCD4, SPRY2, TP63, and KIP2, among others (Meng et al. 2007; Frankel et al. 
2008; Bhatti et al. 2011; Kwak et al. 2011; Quintavalle et al. 2013; Mishra et al. 2014). 
Fascinatingly, inhibition of miR-21 can cause robust cancer regression in a mouse model 
of lymphoma, demonstrating that tumors can exhibit oncomir addiction (Medina et al. 
2010). 
 The first oncomir ever characterized was the mir-17~92 cluster, so-called 
‘oncomir-1’ (He et al. 2005; Kort et al. 2008). This miRNA cluster encodes four distinct 
miRNA families and has two paralogs in the genome that most likely arose from gene 
duplication events (Figure 1.6) (Tanzer and Stadler 2004). Its various miRNA families 
have been powerfully implicated across many tumor contexts (Olive et al. 2010), and 
inhibition of cluster components can successfully combat tumor growth and survival 
(Olive et al. 2009; Murphy et al. 2013). Key pathways that are validated targets of mir- 
17~92 include TGF-β signaling, PTEN, p21WAF1, E2F transcription factors, and the pro-
apoptotic protein BIM, (Novotny et al. 2007; Petrocca et al. 2008a; Ventura et al. 2008; 
Kim et al. 2009; Olive et al. 2009; Grillari et al. 2010; Hong et al. 2010). 
Although particular miRNAs may be characterized as predominantly tumor-
suppressive or oncogenic, miRNAs are on balance thought to exert generally tumor-
suppressive effects in cancer. This thinking arises from the observations that 3’UTR 
shortening occurs in rapidly proliferating (Sandberg et al. 2008) and neoplastic cells 
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(Mayr and Bartel 2009), which would allow mRNAs to escape miRNA regulation. 
Moreover, DICER expression is reduced in lung cancer and this loss is associated with 
poor prognosis (Karube et al. 2005). Indeed, DICER loss or mutation is associated with 
tumor progression in several cancer contexts, and knockdown of miRNA processing 
machinery has been shown to drive tumor progression (Kumar et al. 2007; Hill et al. 
2009; Kumar et al. 2009; Lambertz et al. 2010). Also, transcription factors that are known 
positive regulators of miRNA expression are frequently mutated or functionally impaired 
in cancer, including SMAD proteins and TP53 (Davis et al. 2008; Maitra and Hruban 
2008; Suzuki et al. 2009). It has additionally been shown that defects in XPO5 (Melo et 
al. 2010) or TRBP (Melo et al. 2009) can severely impact global miRNA maturation in 
some cancers. 
 Counter to these observations, mutations in DICER or other components of the 
miRNA biogenesis pathway are not seen in PDAC, and miRNA upregulation is more 
common than downregulation in this disease (Bloomston et al. 2007; Zhang et al. 2009; 
Frampton et al. 2014). This suggests that miRNAs may play an oncogenic role in the 
promotion of pancreatic tumorigenesis and that mutations in the miRNA processing 
machinery are selected against during tumor evolution.  
 
Scope of Thesis 
 
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal malignancies 
in the United States, with an average five-year survival rate of just 6.7%. Advancements 
in the understanding of PDAC molecular biology are desperately needed in order to 
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improve patient survival and quality of life. miRNAs are powerful regulators of gene 
expression that can behave as oncogenes or tumor suppressors, and understanding their 
role in disease processes will inform our understanding and potentially lead to new 
therapeutic approaches. 
This dissertation encompasses two studies exploring the role of miRNAs in 
pancreatic tumorigenesis. In Chapter II, I test the hypothesis that the mir-17~92 cluster of 
miRNAs promotes KRASG12D-driven pancreatic tumorigenesis. I present evidence that 
loss of this miRNA cluster inhibits PanIN development and also promotes PanIN loss and 
acinar regeneration in the context of continuing KRASG12D signaling. This phenotype is 
associated with reduced ERK activity in PanIN lesions. Moreover, mir-17~92-deficient 
tumors are less invasive in vivo, and cell lines derived from these tumors are less invasive 
in vitro. I demonstrate that antagonizing the activity of miR-19 family miRNAs is 
sufficient to suppress the invasiveness of mir-17~92-competent PDAC cell lines from 
mice and humans. Thus mir-17~92 regulates pancreatic tumorigenesis and progression. 
Chapter III presents my exploration of the hypothesis that miRNA biogenesis 
broadly promotes pancreatic tumorigenesis. I find that Dicer heterozygosity inhibits 
PDAC metastasis, but it does not appear to alter other aspects of tumor biology. 
Phenotypic characterization of cell lines derived from tumors in this study suggests that 
the failure of Dicer-heterozygous tumors to metastasize is attributable to an increased 
sensitivity of these cancer cells to anoikis. Ongoing experiments will determine whether 
shifts in miRNA signatures between cell lines can be attributed to this phenotype. 
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Unrelated work regarding the preclinical testing of a triple-drug therapeutic regimen to 
treat advanced pancreatic cancer is presented in Appendix A. 
49 
 
 
 CHAPTER II 
mir-17~92 Promotes Pancreatic Tumorigenesis and Progression 
 
Introduction 
The mir-17~92 cluster, expressing miRNAs from the miR-17, -18, -19, and -92 
families, is upregulated in numerous cancers, including pancreatic cancer (Olive et al. 
2010). Profiling of human pancreatic tumors and pancreatic cancer cell lines has shown 
that miRNAs from the mir-17~92 cluster and its paralogs, mir-106b~25 and mir-
106a~363, are upregulated compared to samples of normal pancreatic tissue or chronic 
pancreatitis (Volinia et al. 2006; Szafranska et al. 2007; Ohuchida et al. 2012). mir-17 
expression in pancreatic tumors has been associated with reduced survival in humans, 
and its overexpression in human pancreatic cancer cell lines accelerates growth and 
promotes invasion (Yu et al. 2010). miR-17 levels in the serum of patients with 
pancreatic cancer also correlates with tumor stage and the presence of metastasis (Que et 
al. 2013). Other studies have found elevated levels of mir-18 (Morimura et al. 2011) and 
miR-25 (Ren et al. 2012) in the blood of patients with pancreatic cancer. A fairly recent 
study using laser capture microdissection of PanIN lesions found that mir-18, -17*, and -
93 were upregulated in PanINs compared to normal tissue, and miR-18 and -93 were 
further elevated in PanIN-3 lesions compared to earlier PanIN grades (Yu et al. 2012a). 
Together these data provide strong correlative evidence for the oncogenic role of mir-
17~92 family miRNAs in pancreatic carcinogenesis. 
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Functional studies of the role of mir-17~92 in pancreatic cancer are rare. One 
study found that simultaneous inhibition of all six miRNAs from the mir-17~92 cluster 
with pooled antagomirs impaired soft agar growth in some human pancreatic cancer cell 
lines (Kent et al. 2009). Another study identified upregulation of miR-106a in pancreatic 
cancer cell lines and linked its pro-invasive role to the suppression of TIMP2 (Li et al. 
2014). No in vivo studies of the cluster in mouse models of pancreatic tumorigenesis have 
been published. Therefore, based on the abundance of clinical data linking the mir-17~92 
cluster to pancreatic cancer progression and the clear need for a better understanding of 
the functional role these miRNAs play in this context, I sought to experimentally test the 
role of these miRNAs in a mouse model of pancreatic cancer. 
The mir-17~92 cluster is essential for proper development in mice and humans 
(Ventura et al. 2008; de Pontual et al. 2011; Hemmat et al. 2014) and germline deletion 
of mir-17~92 is lethal due to ventricular septal defects and lung hypoplasia (Ventura et 
al. 2008). Therefore in the following experiments, I make use of conditional alleles to 
delete the cluster specifically in the pancreas, thereby allowing me to determine the role 
of these miRNAs in pancreatic tumorigenesis and progression. The study itself integrates 
two model systems: the first measures effects of mir-17~92 loss on precursor lesion 
development in the presence of oncogenic KRASG12D, and the second model incorporates 
tumor suppressor deficiency to accelerate progression and tumor formation, thereby 
allowing me to study the role of the cluster in later stages of disease. 
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Results 
To determine the effect of mir-17~92 loss on pancreatic development, I induced 
pancreas-specific cluster deletion using the conditional allele mir-17~92flox and the 
recombination driver Ptf1a-Cre (Figure 2.1a). Importantly, mir-17~92flox/flox, Ptf1a-Cre 
mice robustly lose expression of the cluster, as measured by qRT-PCR on whole pancreas 
RNA (Figure 2.1b), yet they experience normal organ development, with typical exocrine 
and endocrine architecture and composition (Figure 2.1c). Thus the mir-17~92 cluster is 
dispensable for normal pancreas development.  
To assess the impact of mir-17~92 deletion on PanIN development, I crossed 
conditional cluster mice onto the LSL-KrasG12D background (for the LSL-KrasG12D allele 
schematic, see Figure 2.1a). Breeding pairs were designed with mir-17~92flox/wt, LSL-
KrasG12D and mir-17~92flox/wt, Ptf1a-Cre individuals to generate littermate mir-17~92wt/wt, 
LSL-KrasG12D, Ptf1a-Cre (‘KC’) and mir-17~92flox/flox, LSL-KrasG12D, Ptf1a-Cre (‘17KC’) 
mice. Littermate KC and 17KC animals were aged to four or nine months and 
subsequently sacrificed to obtain pancreata for histological analysis. At both ages, I 
observed greater amounts of healthy acinar tissue in 17KC animals than KC animals 
(Figure 2.2a-i). I also observed that 17KC pancreata contained less PanIN tissue by area 
than KC pancreata at nine months. 17KC animals gained healthy acinar tissue with age, 
whereas KC animals completely lost their acinar tissue by nine months. However, the 
distribution of PanIN grades shows no difference between genotypes (Figure 2.2j). These 
data suggest that loss of mir-17~92 impacts PanIN development and maintenance but not 
PanIN progression. 
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Figure 2.1. Homozygous loss of mir-17~92 in the pancreas is developmentally tolerated. 
(A) Deletion of conditional alleles in the pancreas is achieved by driving Cre recombinase from the 
endogenous Ptf1a promoter. Activated Kras
G12D
 is expressed upon deletion of an upstream stop 
cassette flanked by lox-p sites. The majority of the Tp53
flox
 and the entirety of the mir-17~92
flox
 alleles 
are deleted in a similar fashion. (B) qRT-PCR of whole pancreas RNA shows robust suppression of 
mir-17~92 miRNAs in mir-17~92
flox/flox
, Ptf1a-Cre animals; residual expression likely derives from 
endocrine and stromal components not targeted by Ptf1a-Cre. Expression of the related cluster mir-
106b~25 is unaffected. (C) mir-17~92
flox/flox
, Ptf1a-Cre pancreata are histologically normal by 
hematoxylin and eosin stain (‘H+E’) with appropriate differentiation and bulk in both exocrine and 
endocrine compartments. 
a b 
c 
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Immunohistochemical staining of these pancreata demonstrate no measureable 
differences in PanIN proliferative or apoptotic markers (Figure 2.3). Other measures of 
PanIN biology, including the stromal activation marker α-smooth muscle actin (α-SMA), 
the Notch pathway effector HES1, and the TGF-β effector phosphorylated SMAD3 
(pSMAD3), also show no difference in the PanINs of KC and 17KC animals (Figure 2.4). 
ADM lesions in 17KC pancreata stain more strongly with pSMAD3 compared to the 
ADM lesions of KC animals at equivalents ages, but early PanINs in both groups are 
negative for this marker (Figure 2.4i-l). However, 17KC PanINs do display marked 
reduction in MAPK signaling, as determined by staining for phosphorylated extracellular 
signal-regulated kinase (pERK) (Figure 2.5). These data suggest that mir-17~92 regulates 
PanIN maintenance by influencing ERK pathway activity downstream of KRASG12D. 
To look beyond PanIN formation and examine the effect of mir-17~92 on 
carcinoma development, I accelerated the KC model by including conditional loss of one 
copy of Tp53 (LSL-KrasG12D, Tp53flox/wt, Ptf1a-Cre; hereafter “KPC” and “17KPC” mice; 
for Tp53flox allele schematic, see Figure 2.1a). I observed that KPC and 17KPC mice 
display similar overall survival, tumor size, and rates of metastatic disease (Figure 2.6a-
c). Carcinoma subtypes were diagnosed by a licensed pathologist and the distributions of 
both groups were found to consist mostly of adenocarcinoma with less frequent poorly 
differentiated forms (Figure 2.6d-f). Histological evidence of invasion was also equally 
prevalent in both groups, and variously involved the stomach, liver, duodenum, colon, 
and spleen (Figure 2.7). Moreover, tumors across both groups exhibited similar rates of  
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Figure 2.5. 17KC PanINs display reduced phospho-ERK staining compared to KC PanINs. 
Immunohistochemical staining of phosphorylated ERK demonstrates substantially reduced 
positivity in 17KC PanINs compared to KC PanINs at both time points. Two examples are 
provided for each to demonstrate representative ranges in positivity. 
KC 
4mo 
17KC KC 17KC 
9mo 
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proliferation and apoptosis as demonstrated by ki67 and cleaved caspase 3 (CC3) staining 
(Figure 2.8). 
17KPC mice sacrificed for illness arising from localized disease (‘localized’ 
17KPC mice) exhibited significantly prolonged survival compared to localized KPC mice 
(Figure 2.9a). Counterintuitively, these mice also had larger tumors than localized KPC 
mice (Figure 2.9b). Due to anatomical complexity around the pancreatic head, localized 
pancreatic cancer in mice can manifest with jaundice (evident in the ears, footpads, or 
pancreas) or GI obstruction, as seen by GI lumen distension upstream of an adhesion with 
the absence of downstream luminal contents (Figure 2.10a,b). 17KPC mice never 
presented with any form of GI or biliary obstruction (Figure 2.10c,d). Together, these in 
vivo findings suggest that loss of the mir-17~92 cluster generates a less invasive form of 
advanced pancreatic cancer, supporting an oncogenic role for this miRNA cluster in 
disease progression. 
To better understand the biology of mir-17~92 deficient pancreatic cancer cells, I 
generated a collection of cell lines from KPC and 17KPC tumors to measure cancer-
related phenotypes in vitro. I measured proliferative capacity by direct counting of 
adherent cell numbers over time and found that KPC and 17KPC cell lines display a 
spectrum of proliferative rates within each group, but there is no significant difference by 
genotype (Figure 2.11a). Similarly, cell lines from both groups display a spectrum of 
proficiency in their ability to grow in a suspended agarose matrix, which measures 
dependence on adhesion signaling for growth and survival (Figure 2.11b). More direct 
measures of cellular survival by trypan blue exclusion assay demonstrate that apoptotic  
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Figure 2.9. Loss of mir-17~92 prolongs survival in the absence of metastatic disease. 
(A) 17KPC survival is significantly longer after mice with metastatic disease are removed from the 
analysis. (B) Localized 17KPC tumors are larger than localized KPC tumors. 
Log Rank and Student’s t test p values: * < 0.05 
a b 
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Figure 2.10. Obstruction, a common feature of localized KPC disease, is never observed in 
17KPC mice. 
(A,B) Metastatic disease is more likely to cause internal bleeding and less likely to present with 
obstruction. (C) 17KPC mice were significantly less likely to present with abdominal distension. 
(D) 17KPC tumors were never observed to cause obstruction of the biliary or gastrointestinal systems.  
Fisher’s exact p values: * < 0.05, ** < 0.01 
a b 
c d 
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rates in normal growth conditions and in the absence of serum are also not significantly 
different between KPC and 17KPC cell lines (Figure 2.11c,d). I also performed transwell 
migration assays to measure each cell line’s capacity to move through a porous 
membrane in response to a serum gradient. A variation of this assay, called an invasion 
assay, includes a layer of Matrigel coating the membrane, the degradation of which is 
required prior to movement through the membrane. I find that 17KPC cell lines as a 
group are significantly disadvantaged in their invasive capacity compared to KPC cell 
lines (Figure 2.11f). However, no differences exist by genotype in their migration across 
uncoated membranes (Figure 2.11e). These data agree with my results in vivo that 17KPC 
tumors are less invasive, and they suggest that this is due to a specific defect in 17KPC 
cancer cells’ ability to manipulate extracellular matrix rather than more general defects in 
cellular locomotion. 
Invasion through basement membranes requires two major activities: degradation 
of the extracellular matrix and attachment-mediated movement through the mobilized 
substrate, which are coordinated in cancer cells by cellular protrusions called invadopodia 
(Chen et al. 1985). Invadopodia can be identified by the colocalization of their core 
protein components actin, cortactin, and paxillin into punctate or rosette-shaped 
structures (Chen 1989; Linder and Aepfelbacher 2003). To better understand the nature 
of the invasive defect seen in 17KPC cell lines, we collaborated with Chris Turner’s lab 
at SUNY Upstate to analyze invadopodia formation by immunofluorescence. They found 
that invadopodia in murine PDAC cell lines take the form of rosettes and that KPC cells 
lines exhibit higher rates of rosette formation than 17KPC lines (Figure 2.12). They  
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also performed FITC-conjugated gelatin degradation assays, which demonstrate that KPC 
lines degrade more substrate than 17KPC lines (Figure 2.12), which aligns with the 
higher prevalence of invadopodia in these KPC cell lines. These data suggest that loss of 
mir-17~92 reduces invadopodia formation. 
The mir-17~92 cluster encodes six miRNAs encompassing four miRNA seed 
families (Figures 1.4, 2.14), implicating thousands of predicted mRNA targets as 
downstream effectors of the cluster’s invasive program. To aid in my determination of 
which miRNA families may be most important in the invasive phenotype, I evaluated 
nine KPC and nine 17KPC cell lines for the expression of miR-17, -18, -19, and -92 
family miRNAs from the three cluster paralogs, mir-17~92, mir-106b~25, and mir-
106a~363. Quantitative RT-PCR demonstrates that 17KPC cell lines are indeed null for 
miRNAs from mir-17~92, however they retain robust expression from mir-106b~25 
(Figure 2.14a,b). In fact, this locus is sufficient to drive expression of miRNAs for the 
miR-17 and miR-92 families to levels close to that observed in KPC lines (Figure 
2.14d,e). This suggests that differences in the expression of miR-17 and -92 families may 
not be responsible for the invasive defect of 17KPC cell lines. However, miR-19 family 
miRNAs are only expressed from the mir-17~92 and mir-106a~363 clusters, and 17KPC 
lines completely lack expression of this miRNA family (Figure 2.14g). Based on the 
partial residual expression of the miR-17 and miR-92 families, and the generally very low 
expression of the miR-18 family (Figure 2.14c,f), I hypothesized that loss of the miR-19 
family was responsible for the defective invasion of 17KPC cell lines. 
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To validate the role for miR-19 family miRNAs in invasion, I utilized antagomirs 
– short oligonucleotides that bind and inactivate miRNAs – to specifically knock down 
miR-19 function in KPC lines with high invasive capacity and varying levels of miR-19 
expression. I first confirmed miR-19 antagomir activity using a β-galactosidase (β-Gal) 
reporter assay. The reporter construct contained the β-Gal coding sequence followed by a 
3’UTR with multiple miR-19 binding sites that stimulate translational suppression in the 
presence of miR-19. In a cotransfection experiment, pooled antagomirs against miR-19a 
and miR-19b enhance reporter activity in the KPC line 9248#1 (Figure 2.15b). However, 
miR-19 antagomirs cannot enhance reporter activity in 8849#3 cells, which have no 
endogenous miR-19 to antagonize (Figure 2.15a,b). 
Transfected antagomirs against miR-19 effectively suppress KPC cell line 
invasion in a Matrigel-coated transwell assay (Figure 2.16a). This response inversely 
correlates to the endogenous expression of miR-19 family miRNAs (Figure 2.16e), 
suggesting a dosage response. Indeed, the cell line with the highest expression of miR-19, 
9415#2, is resistant to antagomirs at a concentration of 50nM, but responds when treated 
with antagomirs at 100nM (Figure 2.16a). Notably, this effect is specific to invasive 
capacity, and antagomir treatment does not significantly affect migration ability across 
uncoated membranes (Figure 2.16c). The human pancreatic cancer cell lines MIA Paca-2 
and PANC-1 are also invasive and express very high levels of miR-19 (Figure 2.16f). 
Treating these human cell lines with miR-19 antagomirs reduces their invasive capacity 
without affecting baseline migration (Figure 2.16b,d). 
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Figure 2.15. A β-galactosidase reporter assay confirms that miR-19 antagomirs inhibit the 
activity of endogenous miR-19. 
A β-galactosidase reporter plasmid encoding a specially designed 3’UTR with miR-19 binding sites 
was cotransfected into cells with either control or miR-19 antagomirs at 50nM. The 8849#3 cell line 
completely lacks miR-19 but the 9248#1 cell line expresses high levels of miR-19 (A). Relative 
density of the colorimetric reaction is plotted with control antagomir-treated samples set to 100 (B). 
p values: ** < 0.01 
a b 
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Figure 2.16. PDAC cell line invasiveness is suppressed by miR-19 antagomirs. 
(A,B) Transwell invasion was measured for cell lines transfected with control or miR-19 antagomirs. 
(C,D) Baseline migration across uncoated membranes served as an internal control. miR-19 
expression levels are shown relative to the murine-specific control snoRNA234 (E) or the cross-
species compatible U6 RNA (F). p values: * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001 
a b 
c d 
e f 
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Discussion 
Loss of mir-17~92 causes PanIN loss and acinar regeneration 
I demonstrate that deletion of the mir-17~92 cluster in the KC mouse model 
results in a significant reduction in the PanIN burden of aged animals. The distribution of 
PanIN grades in 17KC mice remains consistent with that of aged KC animals, suggesting 
that progression is unaffected by loss of the mir-17~92 cluster. Moreover, the difference 
in PanIN prevalence between KC and 17KC mice is less for younger animals than for 
older animals, suggesting that although PanIN formation may be reduced in 17KC 
animals, the predominant effect of mir-17~92 loss is to promote PanIN regression over 
time. Only a single study has shown that mir-17~92-related miRNAs are upregulated in 
human PanINs (Yu et al. 2012a), and in that study these miRNAs did not have the 
strongest association with PanIN grade among the many miRNAs profiled. Therefore the 
absence of progression-related differences between KC and 17KC mice agrees with the 
published human data and does not support a direct role for the mir-17~92 cluster in 
PanIN progression. 
Based on the published role of mir-17~92 in other tumor contexts as a promoter 
of cell cycle progression and as an antagonist of apoptosis, I initially hypothesized that 
the gradual loss of PanINs in 17KC animals was due to a shift in the balance of apoptosis 
and proliferation within these lesions. IHC staining for ki67 and CC3 clearly show no 
differences between KC and 17KC PanINs at either age, suggesting that the loss of 
PanINs in 17KC mice is not due to enhanced cell death and must be occurring by some 
other means. Moreover, aged 17KC pancreata not only lose PanIN content, but also gain 
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acinar content, suggesting that a regenerative process is occurring in parallel with lesion 
regression.  
Acinar-to-ductal metaplasia is a transformative event that converts the normal 
tissue of the pancreas into PanINs and contributes significantly to the neoplastic process 
in mouse models of pancreatic cancer (Kopp et al. 2012). Recent evidence suggests that 
this process is reversible in the pancreas, and mechanisms exist by which PanINs can 
regress back into healthy acinar tissue. Using an inducible-KRASG12D model, wherein 
KRASG12D expression is controlled by doxycycline dosing, one research group has 
demonstrated that withdrawal of KRAS signaling in established PanINs results in the 
regression of these lesions and the recovery of healthy acinar tissue (Collins et al. 2012a). 
The authors of that study also observe the remodeling and loss of the desmoplastic stroma 
around PanINs upon KRASG12D inactivation, and these changes are preceded by a loss of 
phosphorylated ERK in the PanIN lesions. In a critical follow-up study, the authors 
demonstrate that small molecule inhibition of ERK in the setting of continued KRASG12D 
signaling is sufficient to cause PanIN regression and acinar regeneration (Collins et al. 
2014). These data not only provide proof-of-principle that mature PanIN lesions can 
regress and be replaced by healthy acinar tissue, but they also demonstrate that this can 
occur in the continuing presence of KRASG12D signaling. 
Within my own genetic model, KRASG12D remains active in the pancreas 
throughout the lifetime of the animal. Critically, this suggests that whatever molecular 
differences exist between KC and 17KC PanINs are sufficient to overcome continuing 
KRASG12D signaling to promote PanIN loss over time. I am able to demonstrate that loss 
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of mir-17~92 results in reduced phosphorylated ERK in the PanIN lesions of 17KC 
animals, but does not increase cell death, as measured by CC3 staining. This finding 
aligns well with the published work of Collins et al, who also showed that inhibition of 
ERK signaling does not stimulate apoptosis, and instead appears to promote the 
redifferentiation of PanINs into acinar cells (Collins et al. 2014). Together, these data 
suggest that the loss of PanINs in 17KC animals may indeed be occurring by direct 
regression back into acinar tissue, thereby simultaneously reducing PanIN burden while 
increasing acinar content within 17KC pancreata. Importantly, phosphorylated ERK is 
not completely lost in 17KC PanINs, which could explain why PanIN regression was 
incomplete at nine months in my study, whereas small molecule inhibition of ERK or 
withdrawal of KRASG12D signaling are capable of much more rapid changes (Collins et 
al. 2014). 
The results of my in vivo study of PanIN formation clearly demonstrate that loss 
of the mir-17~92 cluster promotes PanIN loss over time, yet in the tumor study, where I 
additionally delete one copy of Tp53, tumor formation and overall survival are not 
impacted. Moreover, pancreas tissue adjacent to tumors harvested in this study show 
qualitatively similar and very high rates of PanIN formation (data not shown). This 
suggests that the tumor suppressive effect of reduced mir-17~92 expression is overcome 
by the pro-tumorigenic effect of Tp53 loss in this model. A recent paper showed that the 
TP53 effector protein CDKN1A (aka p21WAF1) is highly upregulated in acinar cells 
downstream of TP53 activation during acute pancreatitis, but it is strongly downregulated 
in ADM lesions (Grabliauskaite et al. 2015). In their mouse model, complete loss of 
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CDKN1A accelerated cerulean-induced ADM, suggesting that CDKN1A protects the 
acinar differentiation state in the setting of pancreatitis. Interestingly, absence of 
CDKN1A did not impair pancreas regeneration after withdrawal of the inflammatory 
stimulus (Grabliauskaite et al. 2015). Together, these data suggest that an intact TP53 
response helps to maintain the acinar differentiation state and that its downregulation 
promotes ADM. Thus, 17KPC animals likely experience enhanced progression into 
ADM compared to 17KC animals due to the genetic impairment of Tp53 function and a 
subsequent reduction in CDKN1A activity. Given the long timeline of PanIN loss and 
acinar recovery observed in 17KC mice, it is conceivable that the increased exuberance 
of ADM inherent to the 17KPC model simply overbalances the regenerative effect of 
mir-17~92 loss, resulting in no appreciable difference in the PanIN or tumor formation of 
17KPC mice compared to KPC mice. Interestingly, CDKN1A is a validated target of the 
miR-17 family (Fontana et al. 2008; Hong et al. 2010), suggesting a direct role for 
CDKN1A in the redifferentiation phenotype of 17KC animals. Although the work by 
Grabliauskaite and colleagues suggests that CDKN1A does not promote redifferentiation, 
higher levels of acinar CDKN1A in 17KC mice may contribute to locking 
redifferentiated cells into an acinar state and resisting reentry into ADM. A necessary 
experiment will be to return to the PanIN study and stain for CDKN1A to see if levels 
within acinar cells are higher in 17KC versus KC mice. 
Extending the idea of balance between ADM and redifferentiation, another 
interesting question is whether cluster-dependent differences in PanIN formation would 
be even greater in an adult-induced model, such as the published iKras model (Collins et 
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al. 2012a). It is known that activating KRASG12D in the adult pancreas, as opposed to with 
development, creates a weaker phenotype that additionally requires pancreatitis to 
generate PanINs (Guerra et al. 2007). This suggests that mature pancreatic tissues are 
more resistant to KRASG12D-driven ADM. It is possible that the resistance of 17KC mice 
to PanIN formation is overcome by the aggressive metaplasia that occurs with activation 
of KRASG12D during development, and that adult tissues might be even more responsive 
to regenerative pressure in the absence of mir-17~92. Indeed, perhaps it is the resistance 
of adult tissues to ADM that preserves acinar cells in 17KC mice, whereby 
developmentally driven PanINs lacking mir-17~92 redifferentiate in adulthood and find 
themselves now resistant to the effects of KRASG12D, subsequently persisting as acinar 
cells. 
 
mir-17~92 and transforming growth factor-β 
Activation of TGF-β is a watershed event in pancreatic tumorigenesis because of 
its prevalence in ADM, which drives the majority of PanIN formation. I have personally 
observed that TGF-β signaling is strongly increased in ADM lesions but largely absent 
from early stage PanIN lesions, and this signaling may be stronger in 17KC animals 
(Figure 2.4i-l). TGF-β is a known driver of EMT in a variety of contexts, and it is 
confirmed to have this activity in cultured pancreatic duct cells (Shin et al. 2011). Besides 
stimulating EMT, TGF-β signaling also triggers growth arrest by the induction of 
CDKN1A (Petrocca et al. 2008b) and has been suggested to antagonize ERK signaling by 
a SMAD-independent mechanism (Giehl et al. 2000). Thus TGF-β simultaneously 
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stimulates invasiveness and growth inhibition through several downstream effectors. It is 
well known that this tumor-suppressive role of TGF-β is bypassed in later stages of 
disease by the mutation of SMAD4 (Bardeesy et al. 2006b; Ijichi et al. 2006; Izeradjene 
et al. 2007). 
Published literature on the oncogenic role of mir-17~92 and its paralogs 
characterizes them as potent suppressors of TGF-β signaling, particularly by suppression 
of CDKN1A (Petrocca et al. 2008a; Petrocca et al. 2008b), SMAD4 (Fuziwara and 
Kimura 2014), and TGFBR2 (Volinia et al. 2006). Therefore, upregulation of the mir-
17~92 cluster is predicted to bypass TGF-β-driven growth arrest during ADM. This may 
suggest that growth arrest occurs at higher rates in the ADM lesions of 17KC animals. 
Perhaps this contributes to reduced PanIN burden in these animals. Interestingly, it has 
been shown in BRAFV600E-driven thyroid cancer that mir-17~92 is upregulated by the 
NOTCH effector HES1 and suppresses SMAD4 via miR-19 to drive proliferation 
(Fuziwara and Kimura 2014). Similarly, I observe prominent nuclear HES1 staining in 
ADM and PanIN lesions (Figure 2.4e-h), suggesting that NOTCH1-driven mir-17~92 
may act to suppress SMAD4 in KC animals, thus increasing the number of cells that 
successfully bypass cell cycle arrest. If this is the case, an interesting question will then 
be whether arrested cells persist in a mesenchymal state, undergo mesenchymal-to-
epithelial transition (MET) to achieve an arrested PanIN state, or regress to an acinar 
differentiation state. The final identity of these cells could have major ramifications on 
disease progression, and could differ between KC and 17KC animals. 
 
79 
 
 
mir-17~92 potentiation of ERK signaling - speculation 
As for how mir-17~92 might normally act to enhance KRASG12D signaling 
through ERK, that remains an important question. Ultimately, an unbiased approach to 
identifying miRNA targets would compare the results of prediction algorithms with RNA 
sequencing data to identify significantly downregulated transcripts that are also predicted 
targets of mir-17~92 cluster. Without RNA sequencing data there is a significant lack of 
support for choosing any particular predicted target as a likely player in the PanIN 
phenotype. However, in the absence of that data, speculation may suggest interesting 
relationships. 
Dual-specificity phosphatases (DUSPs) are well known to regulate the 
phosphorylation status of numerous MAPK family proteins, including ERK, JNK, and 
p38 (Rios et al. 2014). Several DUSPs have been implicated in pancreatic cancer 
progression and survival via modulation of MAPK signaling, including DUSP1 (Liu et al. 
2014), DUSP6 (Furukawa et al. 1998; Furukawa et al. 2005; Xu et al. 2005), and 
DUSP10 (He et al. 2014a). Because each DUSP simultaneously regulates multiple 
MAPK proteins, predicting their activity in a given cellular context is impossible, but 
validated relationships from the literature and predicted miRNA-mRNA interactions 
suggest a mechanism for mir-17~92’s regulation of ERK signaling, which is explored in 
the following discussion and summarized graphically in Figure 2.17.  
DUSP10 is a validated target of miR-92, and its suppression is required for JNK 
signaling and the proliferation of human pancreatic cancer cell lines (He et al. 2014a). 
The miR-17 family has been validated to suppress DUSP2 to drive ERK phosphorylation 
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in endometrial stromal cells (Lin et al. 2012). DUSP2 and DUSP7 preferentially suppress 
ERK activity over JNK or p38 MAPKs (Keyse 2008), and DUSP7 is a predicted target of 
both the miR-17 and miR-19 families by TargetScan analysis. Interestingly, MYC has 
been shown to regulate DUSP2 and DUSP7 in pluripotent stem cells (Chappell et al. 
2013), and MYC itself drives transcription of mir-17~92 (O'Donnell et al. 2005), 
suggesting that mir-17~92 may be a necessary facilitator of ERK signaling downstream 
of MYC in cancer contexts. An intriguing study showed that DUSP10, which 
preferentially dephosphorylates JNK and p38, also inhibits ERK activity in a 
phosphatase-independent manner by binding and sequestering phosphorylated ERK in 
the cytoplasm and preventing its activation of downstream targets or transcription 
(Nomura et al. 2012). Lastly, a tantalizing study showed that TGF-β induces ERK 
dephosphorylation in pancreatic cancer cells through the SMAD4-independent activity of 
an unidentified phosphatase (Giehl et al. 2000). Thus, DUSP2, DUSP7, and DUSP10 
represent a cancer-relevant anti-ERK regulatory network that may be potently and 
coordinately suppressed by multiple miRNAs of the mir-17~92 cluster (Figure 2.17). In 
particular, this network integrates signaling from key players in KRAS-driven pancreatic 
cancer, including KRAS signaling, TGF-β signaling, and MYC. Confirmation of these 
relationships will be critical follow-up experiments to the body of work presented in this 
chapter. 
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Figure 2.17. A potential mechanism for mir-17~92 promotion of ERK activity. 
Grey bars are predicted miRNA-mRNA target relationships or uncertain biological activities of 
proteins. Black bars are validated relationships from the literature. DUSP10 regulation of ERK is 
dashed to denote phosphorylation-independent suppression. MYC drives the expression of all 
members of mir-17~92, not just miR-17. 
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miR-19 promotes pancreatic cancer invasion 
Promoting tumor progression by heterozygous deletion of Tp53 creates tumors in 
both KPC and 17KPC mice. Tumors across these two genotypes are similar in size, 
pathological subtype, metastatic capability, proliferation, and apoptosis. The singular 
difference attributable to loss of the mir-17~92 cluster appears to be a reduced 
invasiveness of primary tumors in vivo. I determined that tumors were less invasive in 
vivo by stratifying mice into metastatic or localized groups and observing that mice 
which were sacrificed for severe illness arising from localized disease survived longer 
and with larger tumors in the absence of mir-17~92. The rationale for this stratification is 
that metastasis and local invasion may represent biologically distinct processes, whereby 
entry into the circulation may present different and unique challenges compared to 
extended invasion through dense desmoplastic stroma to reach adjacent organs. This is 
supported by the observation that 17KPC tumors are not significantly different from KPC 
tumors in their ability to metastasize to the liver or peritoneum. Admittedly, histological 
evidence of invasion appears with equal frequency between the two groups, suggesting 
that invasion is eventually achieved and represents the common endpoint of mice dying 
from localized disease; however 17KPC tumors grow larger and require more time in 
order to reach equivalently invasive stages compared to KPC tumors. 
These findings were nicely paralleled in vitro by my observations that KPC and 
17KPC cell lines performed equivalently in growth and survival measurements, but 
17KPC cell lines were particularly deficient in their invasive capabilities in a transwell 
assay. This correlates to a reduction in the presence of invadopodia, which are critical 
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structures for the execution of invasion through extracellular matrix. It is also consistent 
that gelatin degradation generally aligns with the prevalence of invadopodia formation 
between cell lines. For example, 9025#2 forms more invadopodia than 8745#3, and is 
also more effective at degrading gelatin. 
Interestingly, however, 9025#2 is less invasive than 8745#3 in a transwell assay. 
This might suggest at first that although 9025#2 cells are more capable of degradation, 
they may be deficient in chemotaxis, but the migration assay confirms that they are 
migration-competent and, indeed, perform far better than 8745#3 cells. This highlights 
the complex and coordinated nature of cancer cell invasion. For instance, I have not 
characterized whether 17KPC or KPC cell lines exhibit differences in their adhesion to 
particular substrates. Specifically, 9025#2 cells may be more migratory than 8745#3 cells 
in an uncoated transwell assay, but they may be less capable of moving on Matrigel 
components, which would render their increased invadopodia and gelatin degradation 
advantage irrelevant. Moreover, these cell lines still exhibit predominantly epithelial 
morphology as well-differentiated ductal adenocarcinomas, and the dynamics of cell 
separation or collective migration have not been assessed. 
Although I observe significant genotype differences in transwell invasion, 
invadopodia, and gelatin degradation, the specific contributions of these or other deficits 
within individual 17KPC cell lines dictate their net invasive capacity. While it seems 
clear that 17KPC tumors and cell lines are invasion defective, I must also acknowledge 
that there may be untested factors that are different by genotype and are also critical to 
17KPC biology. 
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My finding that invasion can be suppressed with just miR-19 antagomirs greatly 
simplifies the range of potential targets that could mediate and inform our understanding 
of the 17KPC invasion defect. Critically, I have not yet determined whether invadopodia 
formation is suppressed by treatment with miR-19 antagomirs, although these 
experiments will be performed in the near future in collaboration with the Turner lab at 
SUNY Upstate. Moreover, I plan to send cell line RNA for sequencing to determine 
which transcripts are significantly downregulated in KPC cell lines compared to 17KPC 
cell lines, in order to facilitate the identification of relevant miR-19 targets. Awaiting 
these data, we can theorize as to the potential mechanisms of mir-17~92-driven 
invasiveness by considering known biology governing invadopodia. 
SRC is a major regulator of invadopodia rosette formation (Oikawa et al. 2008). 
Several components of invadopodia are targets of SRC phosphorylation, including 
cortactin, CAS, ASAP, and paxillin (Thomas et al. 1995; Brabek et al. 2004; Bharti et al. 
2007). Since its initial characterization as a SRC substrate, paxillin has been variously 
shown to be phosphorylated downstream of EGF (Hetey et al. 2005), TGF-β (Tumbarello 
and Turner 2007), and AKT (Zhao et al. 2010), all of which are pathways relevant to 
pancreatic carcinogenesis. Phosphorylation is responsible for paxillin’s localization to 
peripheral actin and focal adhesions (Nakamura et al. 2000), where it acts to scaffold 
proteins required for invadopodia assembly (Deakin et al. 2012). Interestingly, it has 
recently been shown that MAP3K2 can trigger the ubiquitination of paxillin and force its 
cytoplasmic redistribution away from focal adhesions (Ameka et al. 2014). MAP3K2 is 
predicted to be powerfully and coordinately regulated by the mir-17~92 cluster: its 
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3’UTR contains five predicted binding sites for the miR-17 family (one 8mer site, three 
7mer-m8 sites, and one 7mer-A1site) and two sites for miR-19 (one 8mer and one 7mer-
m8). This suggests that MAP3K2’s expression and activity may be higher in 17KPC cell 
lines as a result of mir-17~92 loss, potentially promoting paxillin delocalization and 
inhibiting invadopodia stability. Based on immunofluorescence in the cell lines thus far 
analyzed, it is not clear that paxillin localization is significantly different between KPC 
and 17KPC cell lines, but this will need to be quantified to rule out slight, but significant 
differences not appreciable by qualitative assessment. 
Regulators of Rho GTPase activity, including Rho GAPs and GEFs, also present 
clear opportunities for miRNA regulation of cytoskeletal dynamics during invasion. 
DLC1 is a Rho GAP that inhibits tumor growth and invasion (Healy et al. 2008; Zhou et 
al. 2008). DLC1 has even been shown to regulate paxillin function in focal adhesions 
(Kaushik et al. 2014). DLC1 is a predicted target of miR-19 (one 8mer) but is not 
predicted to be targeted by any other members of the mir-17~92 cluster, opening up the 
possibility that this Rho GAP could be a miR-19-specific target responsible for invasive 
differences in 17KPC cell lines. Given that paxillin is phosphorylated downstream of 
AKT  (Zhao et al. 2010), another obvious candidate gene to interrogate will be PTEN, 
which antagonizes AKT activity, is a validated target of miR-19, and is a key component 
of the oncogenic activity of the mir-17~92 cluster in lymphoma (Olive et al. 2009).  
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PanIN formation is a reversible process 
Previous to the work presented in this chapter, the only documented way to 
achieve PanIN regression and pancreas regeneration after oncogenic insult was by direct 
inhibition of KRASG12D or ERK signaling. Because KRASG12D inhibition is clinically 
ineffective, and small molecule MEK inhibitors carry toxicity (Welsh and Corrie 2015), 
the implication that the mir-17~92 cluster controls ERK signaling opens up opportunities 
to explore alternative approaches to the medical treatment of precursor lesions. If the 
critical intermediary of mir-17~92-mediated ERK dephosphorylation is a dual-specificity 
phosphatase (DUSP), it could present an opportunity to treat PanIN lesions medically 
with gene therapy. Specifically, a pancreas-targeted adeno-associated virus (AAV) could 
be used to deliver a miRNA-resistant version of the critical DUSP to PanIN lesions. Such 
pancreatic-duct targeted AAVs are already in development for the treatment of cystic 
fibrosis in pigs and are being tested in mice (Guo et al. 2013; Griffin et al. 2014). 
Alternatively, since ERK activity is critical to PanIN maintenance, another approach 
could be to use such pancreas-tropic AAVs to deliver shRNAs targeting upstream 
activators of ERK, or ERK itself. 
Such methods will have to await the final development of the requisite AAV 
tools, but they could be our first attempt at non-surgical prophylactic therapy in healthy 
at-risk individuals. In particular, at-risk individuals with a family history of pancreatic 
cancer could be put on a gene therapy regimen designed to regress a significant bulk of 
their PanIN lesions back to healthy exocrine tissue. Given the long timeline of pancreatic 
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carcinogenesis, a histological reset such as this could result in tremendous gains of life, 
even if it was not curative. Moreover, gene therapy has the potential to be radically less 
toxic and more efficacious compared to prophylactic inhibitor therapy, given that it could 
be delivered in a tissue-specific manner and in a few doses, as opposed to chemical 
inhibitors, which must be dosed continuously and systemically. I am particularly drawn 
to the idea that PanINs can now be medically targeted using such a prophylactic 
approach, because these lesions, particularly PanIN-1, possess far more predictable 
biology compared to later stages of disease where severe disruption of gene expression 
and tumor evolution render generalized therapy ineffective. 
The diversity of late-stage tumor biology is the reason why targeted therapy of 
invasive or metastatic disease is an entirely separate and far more difficult problem. 
Pancreatic cancer invasiveness is a critical barrier to curative therapy for patients, 
because tumors frequently invade nearby tissues before causing symptoms that trigger 
detection. In particular, the mechanism of very early invasiveness, seen around ADM 
lesions and early stage PanINs, is an even greater mystery for its seeming disregard for 
the classical paradigm of carcinoma progression (Rhim et al. 2012). According to the 
work of Rhim and colleagues, ADM allows epithelial-derived cells to disseminate into 
the stroma and even into the circulation where they can seed and survive in the liver long 
before the advent of carcinoma. The presence of circulating pancreatic cells in humans 
with benign precursor lesions has since been confirmed (Rhim et al. 2014b). This is 
starkly different from other carcinomas like colon cancer that progress through benign 
hyperplastic stages to ductal carcinoma in situ prior to invading. Indeed, this suggests a 
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unique biology for pancreas cancer, where a significant number of cancer cells may exist 
outside the pancreas even in those patients with localized disease. This makes a great deal 
of sense with the clinical data that clean surgical resection offers only a 25% chance of 
surviving five years: clearly pancreatic tumors are not bound by their surgical margins. 
However, this is merely conjecture, as the malignant potential of these early-invasive 
cells or their effects on tumor progression have not been demonstrated. Suffice to say that 
our ability to use chemotherapy and radiation to combat metastatic disease is severely 
limited by the biological diversity of metastatic cells, and our best chance at clinical 
benefit in the near future may be interventions against PanINs. 
The interplay of mir-17~92 and TGF-β signaling in the context of oncogenic 
KRAS is complex, but suggests a link between early metaplastic events and the 
aggressiveness of late stage tumor progression. Importantly, we now appreciate that 
epithelially-derived cells expressing KRASG12D migrate into the stroma and can be found 
near ADM and PanIN lesions (Rhim et al. 2012). These cells possess myofibroblast-like 
morphology and likely play active roles in the biology of the investing stroma around 
PanINs and tumors. It follows that the stroma around KPC and 17KPC tumors therefore 
likely differs due to the genetic differences in these EMT-derived cells. Specifically, mir-
17~92-deficient cells that maintain a mesenchymal state would be predicted to respond 
more strongly to TGF-β signaling. Indeed, it has been shown that miR-19 blunts the 
TGF-β response of hepatic stellate cells and reduces their expression of αSMA and type I 
collagen (Lakner et al. 2012). Therefore cells derived from early EMT events in 17KPC 
mice would contribute to the formation of a denser stroma because of enhanced collagen 
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production compared to similar cells in the KPC group. Subsequently, tumors formed in 
the 17KPC context would find themselves within a denser stroma compared to KPC 
tumors, which would impair their ability to invade adjacent tissues. This conceptual 
model agrees with published work demonstrating that the reactive stroma around 
pancreatic cancer probably acts to limit tumor aggressiveness (Rhim et al. 2014a). 
Therefore early metaplastic events and the genetics governing them may exert a stronger 
influence over the clinical progression of late stage disease than previously appreciated, 
and this emphasizes the need to understand and if possible intervene in these early stages. 
 
PanIN regression and ADM dynamics – future experiments 
The finding that PanINs can regress under certain physiological conditions, 
including mir-17~92 loss, and subsequently be replaced by healthy exocrine tissue, 
suggests that PanINs may revert to acinar tissue directly through an event similar but 
opposite to ADM. However, histological stains, which capture a single moment in time, 
may be unable to distinguish such a redifferentiation event from ADM. Confirmation of 
acinar redifferentiation from PanINs would be genetically possible by the addition of a 
secondary recombination system, such as flippase recombinase (Flp) (Lee et al. 2012a), 
to complement the Cre-lox system of the KC model. 
For instance, a fusion transgene composed of the promoter region of Muc1 and 
the coding sequence of Flp (Muc1-Flp) would be predicted to activate Flp expression in 
cells that express Muc1: namely, early PanIN-1 lesions but not normal ducts or acini 
(Gold et al. 2007). The Flp recombinase recognizes flippase recognition target (FRT) 
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sites in DNA and deletes the intervening genetic sequence in a mechanism similar to that 
of Cre-lox (McLeod et al. 1986). Therefore a Muc1-Flp allele could be combined with a 
gene encoding red fluorescent protein (RFP) with an upstream FRT-stop-FRT cassette, 
similar to the LSL-KrasG12D allele. This ‘FSF-RFP’ allele could itself be driven from the 
ubiquitously expressed Rosa26 locus, which has been used extensively to drive gene 
expression in mouse models (Casola 2010). Importantly, a similar allele has been 
described already and generates no background fluorescence (Rhim et al. 2012). The full 
genetic model for PanIN lineage tracing would therefore consist of LSL-KrasG12D, Ptf1a-
Cre, Rosa26-FSF-RFP, Muc1-Flp, with or without mir-17~92flox/flox (suggesting the 
shorthand KCRF and 17KCRF). These KCRF mice would be expected to generate 
PanINs similarly to the well-described KC model, but would additionally activate RFP 
upon metaplasia downstream of Muc1 activation. Subsequently, Rosa26-RFP would 
remain constitutively active in all derived cells, including any differentiated acinar cells 
that derived from mature PanINs.  
miRNAs are thought to provide generally subtle regulation of gene expression, 
with the average miRNA-mRNA interaction generating less than a two-fold reduction in 
protein levels (Baek et al. 2008). This suggests that the regeneration phenotype of 17KC 
mice reflects the enhancement of an underlying process inherent to KC mice, rather than 
the acquisition of a completely new ability. It would therefore not be surprising to 
discover a low basal rate of PanIN regression in young KCRF mice in the absence of 
ERK inhibition or mir-17~92 loss. My prediction is that this reversion is normally 
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outbalanced by full KRASG12D signaling through ERK such that acinar regeneration is 
not observed by measuring total acinar content over time in KC mice.  
An additional benefit of the KCRF model is that it could be used to track invasive 
or metastatic cells derived from PanINs and tumors, allowing a higher resolution view of 
the impact of mir-17~92 deletion on tumor progression. KCRF mice could be bred to 
incorporate the Tp53flox allele (‘KPCRF’), which would not only provide a beneficial tool 
for tracking metastatic cells, but also provide an opportunity to use in vivo imaging to 
monitor tumor progression and spread. Importantly, both the Rosa26-FSF-RFP allele and 
the Muc1-Flp transgene can theoretically be bred to homozygosity, which is an important 
advantage in mouse genetics where Mendelian inheritance can make the generation of 
littermate pairs inefficient. Altogether, the KCRF model presents an exciting opportunity 
to confirm the reversibility of 17KC PanINs and more deeply explore the nature of the 
17KPC invasion deficiency. 
Future in vivo experiments exploring the role of mir-17~92 in pancreatic 
tumorigenesis should additionally delete the mir-106b~25 cluster now that we understand 
it to be so highly upregulated in murine pancreatic tumors. The work I present in this 
chapter – particularly the demonstration the miR-19 antagomirs suppress invasion – 
supports a miR-19-centric model of pancreatic cancer invasion; yet I have not determined 
whether other miRNAs of the cluster play a role in the invasive phenotype. Expression 
from the mir-106b~25 cluster may have prevented me from observing defects related to 
miR-17 or miR-92 family activity and is therefore a confounding variable in the above 
experiments. Although I believe I have arrived at meaningful interpretations of the 
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available data, I would be eager to see the results of dual cluster deletion on PanIN 
formation and tumor invasion. 
At the commencement of these studies, no conditional allele for mir-106b~25 
existed. Such an allele would be ideal, but germline deletion of mir-106b~25 is, in fact, 
developmentally tolerated (Ventura et al. 2008). Ventura and colleagues demonstrate that 
combined deletion of mir-106b~25 and mir-106a~363 displays no developmental 
abnormalities, so follow-up studies could even be performed using mir-17~92flox/flox, mir-
106b~25null, mir-106a~363null mice in the KC context to thoroughly determine the effect 
of the loss of these miRNAs in pancreatic carcinogenesis. Moreover, with the rapidly 
evolving technology of the CRISPR-Cas9 system, it is becoming much faster and more 
cost-effective to generate novel and complex mouse models in-house. For example, 
miRNA cluster alleles could be cloned with lox-p sites flanking specific subsets of the 
clusters in order to facilitate tissue-specific deletion of particular miRNA families. These 
alleles could be tested for efficacy in vitro and rapidly transitioned in vivo using CRISPR-
mediated recombination strategies. The development of CRISPR-Cas9 technology is 
beginning to finally give mouse genetics the power and speed that has previously been 
restricted to more facile model organisms, like Drosophila. 
 
Final thoughts 
The work presented in this chapter is consistent with our understanding of 
miRNAs as subtle modulators of gene expression. Specifically, the PanIN regeneration 
phenotype of 17KC animals, although dramatic, is a slow process that occurs over the 
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course of months. Additionally, the invasion defect of 17KPC tumors manifests as a 
slight survival benefit and a slight overall decrease in 17KPC cell line invasiveness. 
Indeed, my ability to demonstrate these differences rests largely in the scale of the 
experiments: sufficient mice were enrolled that stratification of the study data for 
localized disease still resolved a significant survival difference, and profiling eleven cell 
lines generated significant invasion differences, whereas statistical testing of eight-line 
subsets of the data fails to do so (data not shown). 
An advantage of my experimental design is that it examined the role of an entire 
cluster of miRNAs that contains multiple members of the same miRNA families, many of 
which target the same transcripts. This fact improved my chances of seeing phenotypic 
effects, but the subtlety of the resultant phenotypes should serve as a cautionary tale to 
future investigators. miRNAs are certainly critical regulators of cellular processes, but 
assessing their role by individual deletion in vivo is likely to rarely yield meaningful 
results unless the miRNA being investigated is already known to be a dominant regulator 
of a particular process and its activity is unlikely to be substituted by that of another 
miRNA. Barring that, the investigator should be prepared to dissect potential 
redundancies, as in my analysis of the expression of the mir-17~92 paralogs. 
 Tumor progression is an incredibly complex process, involving myriad signaling 
pathways that are interwoven at every level. Moreover, the specific cellular context 
significantly impacts the effect of a given pathway. Accordingly, the expression and 
impact of miRNAs on the various stages of tumor progression is similarly variable, and 
should not be considered as simply ‘tumor suppressive’ or ‘oncogenic.’ Understanding 
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the mechanisms behind miRNA effects in a transcriptome-specific context is an absolute 
necessity, but also an enormous challenge: consider, for instance, the fact that mir-17~92 
can potentially suppress CDKN1A, TGFBR2, SMAD4, PTEN, BIM, MYCN, and a host 
of GAPs and GEFs regulating RAS family proteins, but these signaling pathways 
themselves are under constant flux and selective pressure that varies according to cell 
type, extent of dysplasia, microenvironment, and host physiology. Ultimately, targets 
must be validated using robust RNA sequencing or proteomic technologies, but even 
these are limited by their resolution in a field that now considers each cell as an 
independent and potentially lethal entity. All of this is compounded by random mutations 
in cancers that generate unpredictable shifts in molecular interactions, at times rendering 
our best understanding of normal biology insufficient. To a certain extent, we can expect 
cancers to follow Murphy’s law, where anything that could go wrong, will go wrong. 
These complexities and uncertainty are strong arguments for a focus on cancer 
prevention, although we should never abandon our attempts to understand and treat 
advanced disease. 
 I have demonstrated that loss of mir-17~92 drives the regression of PanINs and 
their replacement with healthy acinar tissue. This work comes on the heels of similar 
studies demonstrating that PanIN regression can occur even in the continuing presence of 
oncogenic KrasG12D through downregulation of ERK signaling. Now, after decades of 
research, we are beginning to gain insight into the ways PanINs may be medically treated 
to prevent pancreatic adenocarcinoma. Perhaps soon we will begin to see a decrease in 
the number of pancreatic cancer cases in this country thanks to innovations in the medical 
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regression of PanINs. Previously, all talk of progress focused on detection, surgery, and 
improved chemotherapeutics, but these treatments carry significant morbidity and risk of 
mortality. It is hard to envision a way that a procedure as radical as the Whipple can be 
made much safer, but perhaps with a greater understanding of the very early stages of 
pancreatic neoplasia, we can prevent patients from ever needing it. My findings regarding 
the role of mir-17~92 in PanIN maintenance reassure me that this is possible, and they 
give me hope that soon this will be a flourishing field of research that will have a positive 
impact on the care of the pancreatic cancer patient. 
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Materials and Methods 
 
Cell Culture 
 All cell lines were grown in high glucose DMEM (Life Technologies #11965) 
supplemented with 10% fetal bovine serum (Atlanta Biologicals #s11150) and 100U/ml 
penicillin/streptomycin (herein ‘complete media’) (Pen/Strep: Life Technologies 
#15140). Cell lines were maintained at subconfluent densities on tissue culture-treated 
dishes and periodically thawed fresh from frozen stocks to maintain low passage number. 
 Proliferation assays were carried out by plating 2.5x104 cells per well of a 24-well 
plate and counting cells at regular intervals by dissociation in 0.25% trypsin (Invitrogen 
#25200) and trypan blue exclusion (Invitrogen #15250061). Doubling time was 
calculated by first plotting the log2 of the cell number against time and fitting a linear 
regression to the data. The slope of this line has units of doubling events/time, thus the 
doubling time is derived by taking the inverse of the slope (i.e. time/doubling event). 
 Migration assays were carried out by plating 2.5x104 cells in serum-free media 
into 8um-porous migration inserts (Fisher #08-774-162) in a 24-well plate. Cells were 
allowed to settle and adhere onto insert membranes for 20 minutes prior to the addition of 
750ul of complete media to the outside of the insert. Cells were then allowed to migrate 
towards the serum gradient for 24 hours prior to methanol fixation and staining with 
Giemsa (Sigma-Aldrich #48900). Nonmigrating cells were wiped from the interior 
surfaces of the insert prior to membrane separation and mounting on glass slides. Cells 
were counted across five 100x fields under the microscope and averaged across two 
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membranes for each experiment. Invasion assays involved the parallel seeding of cells 
onto invasion inserts (Fisher #08-774-122), which require rehydration in serum-free 
media for one hour prior to seeding, but are otherwise processed identically. Invasion 
index was calculated as the number of invading cells divided by the number of migrating 
cells multiplied by 100%. 
 Serum-starvation survival assays were performed by plating 5x104 cells per well 
of a 24-well plate. One day after seeding, cells were treated with complete media or 
serum-free media and incubated for a further 24 hours. At this time floating cells from the 
media and one PBS wash were collected and combined with trypsinized cells from the 
plate surface. This pool of live and dead cells was then pelleted by centrifugation and 
resuspended in 100ul of complete media supplemented with 0.04% trypan blue. Percent 
survival in fed and starved conditions was calculated as live cells divided by total cells 
multiplied by 100%. ‘Baseline survival’ is survival in the fed state, and ‘serum-starvation 
survival’ is survival in the starved state, divided by survival in the fed state, multiplied by 
100%, and therefore measures the additional death that is attributable to the absence of 
serum. 
 Soft agar colony formation was measured by mixing 2x complete medium, made 
from DMEM powder (Invitrogen #12100) in a 1:1 ratio with 1.4% agarose  (Denville 
#CA3510-8) in distilled water. This mixture is created and maintained at 42˚C to prevent 
agarose polymerization, and is used to coat 10cm plates and create a polymerized non-
adherent surface (‘hard agar plates’). A second mixture of 2x complete medium and 0.8% 
agarose is then made and used to resuspend a pellet of 3x105 cells, which are 
98 
 
 
subsequently distributed across three hard agar plates and allowed to polymerize before 
feeding with 8mls of complete media. Colonies are allowed to form for 14 days before 
counting. Quantification consists of counting the total number of colonies greater than 
three cell diameters wide, across eight 50x fields. 
 Antagomir transfections began with seeding of 2.5x105 cells per well of a 6-well 
plate 24 hours before transfection. miRCURY LNA Power Inhibitors (Exiqon #4101004-
100, 4103258-100, and 199006-100; herein ‘antagomirs’) were transfected by combining 
35 picomoles of antagomir with serum-free media to a final volume of 100ul. This was 
then combined with 20ul of Superfect (Qiagen #301305) and vortexed for ten seconds 
prior to incubation at room temperature for ten minutes. Cells were washed in PBS 
immediately prior to the addition of transfection complexes. The transfection mixture was 
combined with 600ul of complete media, the PBS wash was aspirated from the cells and 
the transfection mixture then added drop-wise. Transfection proceeded for three hours at 
37˚C before an additional 700ul of complete media was added to protect against 
dehydration. Cells were fed with fresh media 24 hours after transfection and at 48 hours 
were plated into assays. 
  
Histological Stains 
 Mouse tissues were fixed in 10% neutral-buffered formalin for at least 24 hours 
prior to processing through ethanol to paraffin blocks. Tissues were cut in 5um sections 
onto charged glass slides and allowed to dry overnight before staining. Prior to staining, 
paraffin slides were melted at 60˚C for 15 minutes and cleared through Xylenes (Fisher 
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#X3P) to 100% ethanol. Slides were then rehydrated through a graded alcohol series to 
distilled water. For immunohistochemical stains, antigen retrieval was performed using a 
citrate buffer (Vector Labs #H3300) by microwave heating at low power for 15 minutes. 
When peroxidase-labeled antibodies were to be used, endogenous peroxidases were 
inactivated by incubation in a 3% hydrogen peroxide solution for seven minutes. Tissues 
were then washed twice in TBS-T prior to blocking. When using mouse primary 
antibodies, an optimized Mouse-on-Mouse kit (Vector Labs #BMK-2202) was used 
according to the manufacturer’s instructions. For all other antibodies, tissues were 
blocked in PBS supplemented with 10% normal goat serum. A list of all antibodies and 
conditions used for immunohistochemical stains appears in Table 2.1. Stains were 
developed using ABC (Vector Labs #PK-6101) and Nova Red (Vector Labs #SK-4800) 
kits. Counterstaining was performed with hematoxylin and slides were dehydrated 
through a graded alcohol series and xylenes prior to being mounted in Permount (VWR 
#100496). 
 Hematoxylin and eosin stains were performed according to field standards. The 
quadchrome stain was developed by David Driscoll and consists of a hybrid protocol 
derived from Sirius Red staining for collagen and Alcian Blue staining for mucin. 
Briefly, slides are rehydrated through a graded alcohol series to distilled water. They are 
then incubated in Weigert’s Hematoxylin for one hour before being rapidly washed in 
acidified water (15 dips in 0.5% acetic acid). This is followed by Sirius Red staining for 
one hour, washes in acidified water, Alcian Blue staining for 30 minutes, washes in  
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    Antibody 
  Stain Cat. Number Concentration Time Temp 
C
o
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m
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n
o
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anti-Insulin Dako A0564 1:500 4hr RT 
anti-Glucagon Dako A0565 1:50 4hr RT 
Alexa-fluor-594 
anti-rabbit 
ab150080 1:250 1hr RT 
FITC anti-guinea 
Jackson Immuno: 
706-095-148 
1:500 1hr RT 
Im
m
u
n
o
h
is
to
ch
em
is
tr
y anti-ki67 ab66155 1:600 4hr RT 
anti-CC3 cs-9664 1:800 4hr RT 
anti-αSMA ab5694 1:400 1.5hr RT 
anti-Hes1 CST-11988 1:5000 4hr RT 
anti-pSMAD3 ab52903 1:200 O/N 4°C 
anti-pERK CST-9101 1:400 1hr RT 
Table 2.1 Conditions of immunohistochemical stains. 
Blocking for all stains was performed with PBS supplemented with 10% normal goat serum overnight 
at 4˚C (pSMAD3 was blocked 4 hours at room temperature). RT: room temperature; O/N: overnight. 
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acidified water, and dehydration to xylenes prior to mounting. In this stain, collagen 
appears bright red, mucin is blue, nuclei are black, and cytoplasm is a weak yellow. 
 
qRT-PCR 
 Quantitative RT-PCR for miRNAs was performed as previously described 
(Fiedler et al. 2010). Briefly, total RNA was isolated by homogenization of PBS-washed 
adherent cells in TRIzol reagent (Invitrogen #15596). RNA was extracted to the aqueous 
phase using chloroform and precipitated in 70% isopropanol overnight at -20˚C to ensure 
capture of small RNAs. Pellets were washed in 70% ethanol prior to solubilization in 
DEPC-treated water and long-term storage at -80˚C. 
 cDNA libraries were created by first treating RNA with DNAse (Life 
Technologies #AM1907) to eliminate genomic contaminants. DNA-free RNA was then 
polyadenylated with E. coli poly-A polymerase (New England Biolabs #M0276) at 37˚C 
for 30 minutes prior to the generation of cDNA using a reverse transcription kit 
(Invitrogen #18080). During the RT reaction, a pool of special primers was used to 
generate cDNA copies of polyadenylated miRNAs. These specially designed primers 
encode a 20-nt universal tag, followed by a 15-nt oligo-dT segment, and finally a 2-nt tag 
that tethers the primer to the 3’ end of polyadenylated miRNAs. A pool of all 12 possible 
combinations for the 2-nt tag was used at a final concentration of 50uM to capture all 
miRNAs during cDNA synthesis. A complete list of RT primer sequences appears in 
Table 2.2. All subsequent steps of the cDNA synthesis were conducted according to kit  
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Primer Name Primer Sequence (5' - 3') 
miR-17 CAAAGTGCTTACAGTGCAGGTAG 
miR-106a CAAAGTGCTAACAGTGCAGGTAG 
miR-106b-5p TAAAGTGCTGACAGTGCAGAT 
miR-20a TAAAGTGCTTATAGTGCAGGTAG 
miR-20b CAAAGTGCTCATAGTGCAGGTAG 
miR-93 CAAAGTGCTGTTCGTGCAGGTAG 
miR-19a/b TGTGCAAATCTATGCAAAACTGA 
miR-18a TAAGGTGCATCTAGTGCAGATAG 
miR-18b TAAGGTGCATCTAGTGCTGTTAG 
miR-92 TATTGCACTTGTCCCGGCCTG 
miR-25 CATTGCACTTGTCTCGGTCTGA 
miR-363 AATTGCACGGTATCCATCTGTA 
snoRNA234 GATTTAACAAAAATTCGTCACTACCACTGAGA 
U6 snRNA (mmu/hsa) CATCTCGAGCTAATCTGGTGGG 
RT Primer 1 ACGCATCTATGCGCATATCG TTTTTTTTTTTTTTT AA 
RT Primer 2 ACGCATCTATGCGCATATCG TTTTTTTTTTTTTTT AC 
RT Primer 3 ACGCATCTATGCGCATATCG TTTTTTTTTTTTTTT AG 
RT Primer 4 ACGCATCTATGCGCATATCG TTTTTTTTTTTTTTT AT 
RT Primer 5 ACGCATCTATGCGCATATCG TTTTTTTTTTTTTTT CA 
RT Primer 6 ACGCATCTATGCGCATATCG TTTTTTTTTTTTTTT CC 
RT Primer 7 ACGCATCTATGCGCATATCG TTTTTTTTTTTTTTT CG 
RT Primer 8 ACGCATCTATGCGCATATCG TTTTTTTTTTTTTTT CT 
RT Primer 9 ACGCATCTATGCGCATATCG TTTTTTTTTTTTTTT GA 
RT Primer 10 ACGCATCTATGCGCATATCG TTTTTTTTTTTTTTT GC 
RT Primer 11 ACGCATCTATGCGCATATCG TTTTTTTTTTTTTTT GG 
RT Primer 12 ACGCATCTATGCGCATATCG TTTTTTTTTTTTTTT GT 
Universal Reverse Primer ACGCATCTATGCGCATATCG 
Table 2.2 Primers used in PCR reactions. 
Primer sequences are provided for all qPCR primers used in the study. In all cases primers were 
derived according to the sequence of the mature mouse miRNA based on miRBase records. The 
primer for U6 snRNA is complementary to human and mouse U6 RNA. 
103 
 
 
 
directions. Lastly, samples were incubated with RNase for 20 minutes at 37˚C prior to 
long-term storage at -20˚C. 
 PCR for miRNAs used a slightly modified rapid program to amplify the very 
short miRNA cDNAs: denaturation at 94˚ for 15 seconds, annealing at 55˚C for 30 
seconds, and extension at 70˚C for 34 seconds, repeated 40 times . The reverse primer for 
all miRNA reactions was the sequence of the universal tag present in all 12 RT primers. 
The forward primer for each miRNA was the mature miRNA sequence. A full list of 
primers used to detect miRNAs in the study is presented in Table 2.2. PCR reactions 
were carried out on an ABI Step One Plus machine in 10ul volumes using SYBR Green 
(VWR #95072). 
 CT values were calculated for all miRNA PCR reactions at a uniform threshold of 
absorbance across all experiments and controlled to CT values for the endogenous 
reference (snoRNA234 in mouse-only experiments, U6 in human and cross-species 
comparisons). The expression of individual miRNAs is presented as relative snoRNA234 
units in order to convert the ΔCT value for each miRNA into a relative molar measure 
(calculated as 2ΔCT). Once all miRNAs are expressed in this manner, the expression levels 
of individual miRNAs can be straightforwardly summed to generate a measure of the 
relative abundance of all miRNAs within a shared miRNA family, allowing intra-family 
comparisons between treatment groups or genetic cohorts of cell lines. Because of seed 
family redundancy, this analysis is critical when considering the potential overall effect 
of a miRNA family composed of many differently expressed individual miRNAs. 
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Mouse Breeding, Euthanasia, and Necropsy 
 All mice generated in this study were housed in a dedicated facility in accordance 
with guidelines set forth by the Institutional Animal Care and Use Committee. The alleles 
for mir-17~92flox (Ventura et al. 2008), Ptf1a-Cre (Kawaguchi et al. 2002), LSL-KrasG12D 
(Jackson et al. 2001), and Tp53flox (Jonkers et al. 2001) have been described previously. 
 For the precursor lesion study, mir-17~92flox/wt, Ptf1a-Cre mice were maintained 
on a C57/Bl6 background and crossed to mir-17~92flox/wt, LSL-KrasG12D mice on a mixed 
background to generate littermate KC and 17KC animals. For the tumor survival study, 
mir-17~92flox/wt, Tp53flox/flox, Ptf1a-Cre mice were maintained on a C57/Bl6 background 
(F0 generation) and crossed together to generate littermate mir-17~92
flox/flox, Tp53flox/flox, 
Ptf1a-Cre and mir-17~92wt/wt, Tp53flox/flox, Ptf1a-Cre mice (F1 generation). Littermate mir-
17~92flox/flox, LSL-KrasG12D and mir-17~92wt/wt, LSL-KrasG12D mice were generated in a 
similar fashion. These mice were then used to generate mating cages for the survival 
study. Thus, 17KPC and KPC mice (F2 generation) could be bred with high efficiency 
while preserving genetic relatedness through littermate control of the F1 generations. 
Over the course of the study, experimental animals were generated from mating cages 
formed from at least three separate F1 generations, further protecting study results from 
effects of random genetic drift between KPC and 17KPC breeders. 
 Health status was monitored at least three times per week for all animals. Major 
signs of illness warranting euthanasia included severely reduced mobility with lack of 
arousal upon handling, hunching, abdominal distension, wasting, palpable abdominal 
mass, and hyperventilation. Comorbidities contributing to euthanasia decisions included 
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pallor, squinting, grooming deficits, and abnormal gait. Prior to euthanasia extensive 
notes were gathered regarding general appearance and reasons for sacrifice. Upon 
necropsy, the disposition of the internal organs was noted prior to dissection, including 
distension of any tubular organs, fibrosis, adhesions, metastases, strictures, necrosis, 
jaundice or developmental abnormalities. Tumors were measured in three orthogonal 
directions (length, width and depth) and tumor volume was calculated according to the 
equation    
 
 
 (   ). The presence of adhesions or frankly invasive disease was 
noted, as well as the color, firmness, and location of the tumor within the pancreas 
relative to other structures. Tumors were then subdivided into pieces according to the 
amount of available tissue and the following priority list: 1) fixation (esp. along areas of 
adhesion or likely invasion), 2) cell line, 3) flash frozen samples for protein, RNA, and 
DNA. 
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CHAPTER III 
Partial Loss of Dicer Sensitizes Tumors to Anoikis and Inhibits Metastasis 
 
Introduction 
The lethal nature of pancreatic cancer is largely due to its early invasive and 
metastatic nature, which prevents the majority of patients from undergoing potentially 
curative surgery (Hariharan et al. 2008). Understanding the mechanisms of tumor 
progression, particularly as they relate to the processes of invasion and metastasis, is 
critical to the future of care for the metastatic patient. A major step in a carcinoma’s 
metastatic program is the ability to invade through basement membranes, escape the 
epithelial compartment, and cross into the circulation (Hanahan and Weinberg 2011). 
Subsequent to this, cells must survive in the liquid environment of the circulatory system, 
continue to evade the immune system, reattach at distance sites, invade into foreign 
tissues, and then survive and grow to form a competent metastasis (Chambers et al. 2002; 
Chaffer and Weinberg 2011). These multiple steps exert strong selective pressure on 
tumor cells, and metastatic seeding can be a very inefficient process (Luzzi et al. 1998). 
Nevertheless, for highly metastatic cancers like pancreatic cancer, tumor cells are 
evidently proficient at overcoming such hurdles, and we must better understand the 
means by which they achieve this. 
miRNAs govern nearly every cellular pathway and provide an additional means 
of understanding tumor origins and behavior (Lu et al. 2005). Broad characterization of 
human tumors reveals a general downregulation of miRNA biogenesis in many solid 
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tumors (Lu et al. 2005), indicating a tumor-suppressive role for miRNAs. This is 
supported by observations that widespread shortening of 3’UTRs also occurs in cancer 
(Mayr and Bartel 2009), and suppression of miRNA processing machinery can promote 
tumor progression in several cancers (Kumar et al. 2007; Hill et al. 2009; Kumar et al. 
2009; Lambertz et al. 2010).  
 Until very recently, the broad role of miRNAs in pancreatic cancer has not been 
explored (Morris et al. 2014; Wang et al. 2014). Generally, mutations in DICER or other 
components of the miRNA biogenesis pathway are not seen in PDAC, and miRNA 
upregulation is more common than downregulation in this disease (Bloomston et al. 
2007; Zhang et al. 2009; Frampton et al. 2014). It is also known that miRNAs are broadly 
required for the development and maintenance of pancreatic cell lineages (Lynn et al. 
2007; Morita et al. 2009; Morris et al. 2014). These data collectively suggest that 
miRNAs play an oncogenic role in the promotion of pancreatic tumorigenesis and that 
mutations in the miRNA processing machinery are selected against during tumor 
evolution. A single study has provided preliminary data for the role of Dicer in precursor 
lesion development that largely agrees with the published data from other tumor contexts 
(Morris et al. 2014; Wang et al. 2014), but to date no functional study of the role of Dicer 
in pancreatic tumorigenesis or progression has been described, nor has any explanation 
been proposed for the preservation of miRNA biogenesis in human pancreatic tumors. 
 This chapter describes my investigation into the requirement for Dicer in 
pancreatic tumorigenesis. In agreement with the published literature, I demonstrate that 
complete loss of Dicer creates instability in mature pancreatic lineages, resulting in 
108 
 
 
degeneration of the exocrine pancreas. Dicer heterozygosity is developmentally tolerated, 
and I show that partial loss of Dicer is also permissible for tumor development, but that 
Dicer-heterozygous tumors are deficient in their ability to metastasize to distant sites. In 
vitro experiments link this failure of metastasis to an increased susceptibility to anoikis, 
which is cell death triggered by loss of attachment and is analogous to the stress of 
surviving in the circulation. Efforts to describe miRNA signatures predictive of cell line 
phenotypes and metastasis are ongoing.  
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Results 
 Dicer is broadly required for normal vertebrate development (Harfe et al. 2005; 
Yang et al. 2005; Lynn et al. 2007; O'Rourke et al. 2007). Therefore I made use of the 
Ptf1a-Cre allele to selectively delete conditional alleles of Dicer in the pancreas 
(Mudhasani et al. 2008). In agreement with the published literature, I found that complete 
ablation of Dicer in the pancreas is not tolerated, as evidenced by the progressive 
deterioration and loss of the exocrine compartment in Dicerflox/flox, Ptf1a-Cre animals 
(Figure 3.1b,d,f) (Morita et al. 2009). I observed this at postnatal day 3 as hypomorphic 
acinar cells with reduced zymogen contents compared to Dicerflox/wt, Ptf1a-Cre animals 
(Figure 3.1a,b). This progressed to a pronounced loss of exocrine architecture by six 
months with residual islands of acinar tissue, ducts, islets, and lymph nodes existing 
within a vast expanse adipose tissue (Figure 3.1f). Staining of three-day-old pancreata 
revealed extensive apoptosis in Dicerflox/flox pancreata and a compensatory increase in the 
proliferative rate of acinar cells (Figure 3.2). 
Based on these findings, Dicerflox/flox, Ptf1a-Cre animals did not provide a 
developmentally normal baseline from which to measure differences in tumor formation, 
leading me to compare Dicerflox/wt animals to Dicerwt/wt littermates in the tumorigenesis 
study. It must be noted, however, that Dicerflox/wt animals also exhibit some abnormal 
changes in the form of sporadically ‘vacuolated’ acinar cytoplasm (Figures 3.1g, 3.3c). 
Vacuolization of the acinar compartment does not occur in Dicerflox/wt, Ptf1a-Cre animals 
(Figure 3.3a), but it does occur in the context of Tp53 loss (Figure 3.3b). In these contexts 
I do not observe any deterioration of the pancreas architecture or pancreatic insufficiency 
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Figure 3.3. ‘Vacuolization’ and degeneration are dependent on Tp53 and Dicer status. 
H+E staining was performed on the pancreata of mice from different backgrounds to examine the role 
of Dicer and Tp53 in vacuolization and fatty replacement. (A) Dicer
flox/wt
, Ptf1a-Cre: note the absence 
of acinar vacuoles. (B) Tp53
flox/flox
, Ptf1a-Cre.  (C) Dicer
flox/wt
, Tp53
flox/flox 
, Ptf1a-Cre. (D,E) 
Dicer
flox/flox
, Ptf1a-Cre. (F) Oil Red O stain of Dicer
flox/wt
, Tp53
flox/flox 
, Ptf1a-Cre. Arrows highlight 
vacuoles. 
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in aged animals (data not shown). Exocrine degeneration and fatty replacement occurs 
only upon complete genetic ablation of Dicer (Figure 3.3d,e). These ‘vacuoles’ are 
currently of an unknown composition or origin, but I have confirmed that they are neither 
lipid positive by Oil Red O stain (Figure 3.3f), nor glycogen positive by Periodic Acid 
Schiff stain (data not shown). 
 To induce tumor formation, I used the RCAS-tva system of retroviral gene 
delivery. The RCAS virus (replication competent avian sarcoma-leukosis virus long 
terminal repeat with a splice acceptor) is an engineered vector capable of infecting cells 
expressing the avian cell surface receptor tva (Bates et al. 1993; Young et al. 1993). 
Transgenic mice expressing tva under the control of the elastase promoter are therefore 
susceptible to pancreas-specific infection by RCAS viruses (Lewis et al. 2003a). The 
RCAS virus itself is designed to drive expression of the inserted gene of interest by the 
viral long terminal repeat (Gorman et al. 1982; Norton and Coffin 1987). Using this 
system, our lab has used RCAS virus expressing polyoma virus middle-T antigen 
(RCAS-PyMT) to induce tumors in the pancreas (Lewis et al. 2003a; Ahronian and Lewis 
2014; Sano et al. 2014). PyMT is an oncogene (Chowdhury et al. 1980) that acts to 
recruit signal transduction molecules to endomembranes (Schaffhausen and Roberts 
2009). It is capable of activating the SRC family proteins c-SRC and YES (Bolen et al. 
1985; Thomas et al. 1993), PI3K (Whitman et al. 1985; Summers et al. 1998), and RAS 
via its recruitment of SHC and GRB2 (Campbell et al. 1994). Induction of tumors using 
the RCAS-PyMT system allows the generation of diverse carcinoma subtypes, including  
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acinar carcinoma, ductal adenocarcinoma, and poorly differentiated forms (Lewis et al. 
2003a). Using this system, I sought to determine whether miRNA biogenesis would 
differentially impact the formation of these subtypes. 
I intraperitoneally injected litters of Elastase-tva, Dicervariable, Tp53flox/flox, Ptf1a-
Cre mice at postnatal day 3 with live chicken fibroblasts producing high titer RCAS-
PyMT virus (‘Dicervariable’ signifies that pups were derived from the crossing of 
Dicerflox/wt parents). I then compared the survival of Elastase-tva, Dicerwt/wt, Tp53flox/flox, 
Ptf1a-Cre to Elastase-tva, Dicerflox/wt, Tp53flox/flox, Ptf1a-Cre littermates (herein ‘PC’ and 
‘DPC’ respectively) (Figure 3.4). 
I observed that PC and DPC mice exhibit similar rates of overall survival and 
tumor size (Figure 3.5a,b). Moreover , the distribution of tumor pathologies was also 
similar between groups with similar rates of development of acinar and ductal 
carcinomas, in agreement with published literature regarding PyMT expression in the 
exocrine pancreas (Figure 3.5c-f) (Lewis et al. 2003a; Du et al. 2009). However, DPC 
mice experience significantly lower rates of metastatic disease than PC mice (Figure 
3.5j). Metastases were only observed in the liver and infiltrated into the liver parenchyma 
(Figure 3.5g) or grew intravascularly (Figure 3.5h).  
An extensive panel of cell lines derived from tumors in the survival study was 
characterized in vitro for performance in a variety of cancer-related phenotypes. 
Proliferative capacity, measured by direct cell number over time, shows no difference 
between PC and DPC cell lines (Figure 3.6a). The ability of cell lines to grow suspended 
in an agarose matrix was universally low across PC and DPC cell lines except for   
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Figure 3.6. PC and DPC cell lines exhibit a spectrum of behaviors in proliferative and 
chemotactic assays in vitro. 
No significant differences exist between PC and DPC cell lines in measures of proliferative rate (A), 
anchorage-independent growth (B), migration (C), or invasion through Matrigel (D). The cell line 
10087#1 was isolated from a PC mouse outside the survival study and is not included in statistical 
analyses (see discussion). 
a b 
c d 
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10086#4, and no significant differences existed by genotype (Figure 3.6b). Migration and 
invasion capacity, measured in a transwell assay, were also not significantly different 
between PC and DPC cell lines (Figure 3.6c,d). When assayed for their resistance to cell 
death in a variety of conditions, DPC cell lines were similar to PC cell lines in their 
baseline survival and resistance to serum starvation and gemcitabine (Figure 3.7a-c), but 
they were significantly more sensitive than PC lines to cell death upon loss of attachment 
(‘anoikis’; Figure 3.7d). Therefore, greater sensitivity to anoikis may underlie the reduced 
capability of DPC tumors to metastasize in vivo. 
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Discussion 
 
Dicerflox/flox pancreas degeneration 
It is not surprising that complete loss of Dicer is not tolerated in the pancreas. At 
this point, miRNAs are known to be broadly required for tissue development, 
homeostasis, and cellular survival (Bernstein et al. 2003; Lynn et al. 2007; Lambertz et 
al. 2010; Zhang et al. 2014a). What is interesting, perhaps, is that Dicerflox/flox, Ptf1a-Cre 
animals possess a growing pancreas at birth, but this tissue then slowly regresses and is 
replaced by adipose with time, leaving behind intact islets and isolated portions of the 
ductal system with residual, abnormal acinar tissue. This is a weaker phenotype than that 
observed by Lynn and colleagues, who used Pdx1-Cre to delete Dicer in the pancreas and 
observed severe exocrine degeneration at embryonic stages (Lynn et al. 2007). Pdx1 is a 
transcription factor responsible for the differentiation of both endocrine and exocrine cell 
lineages of the pancreas (Gu et al. 2002), and is expressed earlier in development than 
Ptf1a, which contributes predominantly to exocrine differentiation (Kawaguchi et al. 
2002). My work and the work of Lynn and colleagues together suggest that the timing of 
Dicer deletion is important for its developmental tolerability. 
At this point I do not know the precise mechanism of the acinar regression 
observed in these animals. It could be due to cell death and subsequent replacement by 
infiltrating adipose from adjacent visceral depots. This is supported by the higher rates of 
CC3 staining observed in the pancreata of Dicerflox/flox, Ptf1a-Cre pups. Another 
intriguing possibility is the transdifferentiation of pancreatic parenchyma into adipose. 
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This has been reported once before in animals which were engineered to lose Myc and 
which also expressed pancreatic lineage tracing genes (Bonal et al. 2009). This group was 
able to demonstrate that adipocytes present in the setting of a degenerating pancreas had 
previously expressed the pancreas-specific transcription factor Ptf1a, suggesting that 
these cells had originated from pancreatic exocrine progenitors. The observation of 
vacuolization in DPC pancreata initially offered an enticing clue that this could be 
relevant to my model, but whatever the nature of the observed acinar vacuoles, they are 
not lipid positive. Indeed, the persistence of these vacuoles into late age and the absence 
of exocrine degeneration or intercalating adipocytes in Dicerflox/wt, Tp53flox/flox, Ptf1a-Cre 
animals do not support the idea that this could represent a transition state between acinar 
and adipocyte differentiation. Nevertheless, aged human pancreata exhibit areas of 
adiposity that suggest the potential for acinar cells to transdifferentiate to adipocytes in 
response to stress or some other stimulus. From the perspective of cellular stress, it is 
possible that these vacuolar artifacts represent an aberrant response that is normally 
regulated or prevented in the setting of fully competent miRNA biogenesis. One 
possibility that leaps to mind is that these could be evidence of deregulated autophagy, 
but I have yet to stain these vacuolated tissues for autophagy markers. 
 
Carcinoma subtypes 
 I chose to use the RCAS-tva system of tumorigenesis partly because of its ability 
to induce a variety of different tumor types: acinar, ductal, and poorly differentiated 
carcinoma. One of the questions I wanted to ask was whether miRNA biogenesis was 
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more generally required in one carcinoma subtype or another, hypothesizing that this 
would be reflected in a shift of subtype prevalence in DPC animals compared to PC 
animals. The fact that this was not observed suggests that miRNA biogenesis is not 
preferentially required by one carcinoma more than another.  
 
Circulating tumor cells, anoikis, invasion, and metastasis 
 The major question of this project was whether single-copy loss of Dicer could 
negatively impact tumorigenesis. To this end, I was pleased to find that DPC tumors 
progressed to metastatic disease less frequently than PC tumors. Based on the 
developmental abnormalities of Dicernull pancreata, I initially suspected that the failure to 
metastasize would correlate with an aggressive cell death response. In my initial analysis 
of standard cancer cell phenotypes in vitro, including proliferation, soft agar colony 
formation, migration, invasion, and survival response to serum starvation, I did not 
observe any significant differences by genotype, although there was substantial 
variability across the entire panel of cell lines in most phenotypes. I noticed with some 
surprise that nearly all of the cell lines tested were quite deficient in soft agar colony 
formation compared to pancreatic cell lines I had worked with in the past (see Figures 3.6 
and 2.10). Moreover, at the completion of the soft agar assays, there was also no evidence 
of intact single cells to account for the cells which were seeded and observable at the 
beginning of the assay, suggesting that they had died and degraded. Because I observed 
robust resistance to cell death in serum starvation and standard growth conditions for PC 
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and DPC cell lines, I wondered if the failure to form soft agar colonies represented 
sensitivity to a specific form of cell death caused by the loss of attachment signaling.  
‘Anoikis’ (a neologism from Greek morphemes that roughly translates as 
‘homelessness’) describes the process of cell death in response to loss of extracellular 
attachment signals (Frisch and Francis 1994). When I suspend PC and DPC cell lines in 
media over a non-adherent surface, I observe that both cell lines display aggressive cell 
death over 24 hours, but DPC cell lines are more sensitive than PC cell lines. This 
provided a potential explanation of the in vivo data, suggesting that the reason for the 
reduced metastasis of DPC tumors is the accelerated death of circulating tumor cells 
(CTCs). Notably, in the course of assessing liver metastases in this study, I had observed 
frequent and numerous intravascular inflammatory foci in the livers of PC and DPC mice 
(Figure 3.5i), which I did not observe in the KrasG12D-driven mouse model of pancreatic 
cancer that I used in the studies described in Chapter 2. I now suspect that these foci 
represent an inflammatory reaction to dying CTCs that is characteristic of mice 
possessing tumors driven by RCAS-PyMT. I also observed that a portion of all 
metastases observed in either arm of the study grew intravascularly, further suggesting 
that PyMT-driven CTCs spend a significant amount of time in the vasculature prior to 
extravasation. 
One mouse in particular, 1449#2, provided an exciting opportunity to explore the 
interrelationship of anoikis, extravasation and metastasis. At sacrifice, this DPC mouse 
possessed four large and distinct primary tumors and two distinct liver metastases. I was 
fortunate to be able to successfully derive cell lines from all four primary tumors 
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(1449#2A-D) and both liver metastases (1449#2MA and 1449#2MB), all of which are 
characterized in Figures 3.6 and 3.7. Fascinatingly, 1449#2MA and 2MB are 
simultaneously the most invasive and the most anoikis-sensitive lines across the entire 
study of twenty cell lines. 
Based on the enhanced sensitivity of DPC cell lines to anoikis and their overall 
metastatic deficiency, I had originally suspected that the 2MA and 2MB lines would 
display increased resistance to anoikis compared to other DPC lines, hypothesizing that 
this would promote prolonged intravascular survival and facilitate metastasis. Strikingly, 
the extreme sensitivity of these cell lines to anoikis suggests that their survival in the 
circulation would have been severely challenged; instead it was probably their extreme 
invasive capacity – the highest observed of all cell lines in the study – that facilitated 
their rapid escape from the vasculature and successful metastasis. It is interesting to note 
that three of the top five anoikis-resistant DPC cell lines come from the 1449#2 mouse. 
This suggests that the presence of anoikis-resistant CTCs is still predictive of metastasis, 
but it may suggest a polyclonal model where anoikis-resistant CTCs do not themselves 
possess invasive capacity. Instead, anoikis-resistant CTCs could, through cell-cell 
contacts, provide survival signals to invasion-competent, anoikis-sensitive CTCs, thereby 
giving them more time to extravasate and seed metastases. Such a model would agree 
with my observations of intravascular tumor growth and could suggest that these are a 
necessary staging area for metastatic spread in this model. 
 
125 
 
 
10087#1 and Tp53 context 
 The cell line derived from mouse 10087#1 constitutes an outlier in the study 
because it was isolated from a Cre-negative animal which was in good health at the time 
of sacrifice. This animal had been injected as part of an experimental litter with RCAS-
PyMT and was sacrificed to obtain control pancreas tissue alongside an experimental 
littermate that was showing signs of illness. It was at this time that 10087#1 was noted to 
have a tumor in the head of the pancreas in addition to grossly visible metastases in the 
liver. This tumor therefore developed in the context of intact Tp53 and Dicer, making its 
biology distinct from that of the other PC mice. Moreover, this mouse was sacrificed in 
good health, which is why this animal is not included in the survival analysis and this cell 
line is excluded from statistical testing for differences between PC and DPC cell lines, 
although it is charted in Figures 3.6 and 3.7 for comparison. The behavior of this cell line 
in culture has implications for the influence of Tp53 status on pancreatic cancer biology.  
 The cell line 10087#1 exhibits severely impaired growth compared to nearly all of 
the other cell lines in the study, clearly shown by its long doubling time and its 
exaggerated failure to form colonies in soft agar. It is sensitive to anoikis and serum 
starvation, but resistant to gemcitabine, and its invasive capacity is elevated, suggesting a 
behavioral profile similar to the metastatic cell lines 1449#2MA and 1449#2MB. These 
characteristics also describe the typical clinical picture of pancreatic cancer in humans 
(slow growing, metastatic, invasive, and resistant to gemcitabine). TP53 is not 
completely lost in human pancreatic cancers, and single-copy loss is typically 
complemented by mutational inactivation of the second allele, suggesting an oncogenic 
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role for mutant TP53 in pancreatic cancer progression or maintenance (Redston et al. 
1994). Indeed, the mutated allele Tp53R172H has been shown to cooperate with oncogenic 
KrasG12D to drive metastasis (Hingorani et al. 2005), and mutant TP53 has been shown to 
promote gemcitabine resistance in human pancreatic cancer cells (Fiorini et al. 2015). 
Together these studies agree with the behavior of the 10087#1 cell line, and suggest that 
it likely possesses a mutated allele of Tp53. They also suggest that the metastatic cell 
lines from 1449#2 may have accessed similar biological pathways via some Tp53-
independent mechanism. A recent study has demonstrated that the pro-metastatic nature 
of mutant Tp53 in murine PDAC results from its ability to antagonize TP73 and alleviate 
TP73’s transcriptional repression of the pro-metastatic growth factor receptor PDGFR 
(Weissmueller et al. 2014). This suggests that in the complete absence of TP53, PC and 
DPC cell lines would be expected to be less metastatic due to the suppression of PDGFR 
by TP73. Perhaps the metastatic cell lines of 1449#2 have re-expressed PDGFR to 
enhance their invasive capacity through silencing of Tp73. An in-depth comparison of the 
transcriptional profiles of these cell lines could reveal convergent biology between these 
metastatic cell lines and human pancreatic cancers. 
 
Mechanism of anoikis sensitivity - speculation 
 Many classically cancer-associated growth and survival pathways have been 
implicated in anoikis resistance, including activation of cell surface receptors such as 
EGFR, IGF1R, and integrins, with subsequent downstream activation of MAPK and 
PI3K signaling (Galante et al. 2009; Buchheit et al. 2014). SRC activity is known to drive 
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anoikis resistance in pancreatic cancer cell lines (Connelly et al. 2010), and its activation 
can occur downstream of focal adhesion kinase (FAK) activity (Duxbury et al. 2004a; 
Duxbury et al. 2004b). In pancreatic cancer specifically, it has been shown that MAP3K7 
is important to anoikis resistance through its induction of noncanonical WNT signaling 
(Yu et al. 2012b), and HMGA1 promotes anoikis resistance of MIA PaCa-2 and BxPC3 
pancreatic cancer cell lines via PI3K-AKT pathway upregulation (Liau et al. 2007). 
These studies reveal the early stages of our understanding of anoikis, as they deal broadly 
with identifying the major operant signaling pathways in a few cellular contexts, but fall 
short of identifying unique aspects of anoikis that do not overlap with other general cell 
death pathways. Subsequently, there is little to go on when attempting to interpret a 
specific deficit in anoikis resistance that does not affect cell death responses to other 
stimuli, such as I observe in my characterization of DPC cell lines. 
It has also been suggested that anoikis resistance depends on the ability of the 
upstream driver oncogene to regulate the activity of RHOB, which is a tumor suppressor 
that impairs soft agar colony growth and promotes anoikis. Specifically, oncogenic RAS, 
but not active SRC, is capable of suppressing RHOB activity (Jiang et al. 2004). This 
may suggest why PyMT-driven cancer cell lines, which are predominantly driven by 
SRC signaling, are generally deficient in soft agar colony formation and sensitive to 
anoikis, but this does not offer much interpretation for the additional anoikis sensitivity of 
DPC lines compared to PC lines. A very interesting idea has been proposed that suggests 
miRNA biogenesis may broadly govern cancer stress responses through an ability to 
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buffer aberrant gene expression triggered by mutated gene promoters and enhancers 
(Ebert and Sharp 2012). 
The idea that Ebert and Sharp propose flows partly from the consideration of an 
analogy: mutations in protein coding sequences can be ‘buffered’ by chaperone proteins 
like HSP90 to generate normal cellular functions. Similarly, mutations in upstream 
genetic elements could contribute to aberrant transcriptional activation of genes, which 
could be buffered by miRNA suppression. Integral to this concept is the idea of miRNA 
thresholds (Mukherji et al. 2011), wherein stochastic bursts of transcription in the 
absence of upstream signaling (i.e. ‘leaky’ gene expression) is suppressed by an 
abundance of miRNAs targeting the comparatively low number of leaky transcripts. 
However, transcription driven by ‘intentional’ cellular signaling generates high levels of 
transcripts that overwhelm miRNA suppression to achieve translation. Therefore 
miRNAs act in part to suppress random transcriptional events by requiring a threshold 
level of transcription before gene expression can occur. However, in the context of 
impaired miRNA biogenesis, such as occurs in come cancers, stochastic transcription 
resulting from mutations in upstream repressive elements may achieve translation 
because of a reduced miRNA threshold. Ebert and Sharp propose that this random gene 
expression contributes to selective pressure against cancer cells that have partially lost 
DICER expression and accelerates the development of more malignant phenotypes.  
However, the interrelationship of transcriptional noise, physiological robustness 
and selective pressure could be very different in the specific context of pancreatic cancer, 
compared to other cancers where DICER is a validated tumor suppressor. Pancreatic 
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cancer is characterized by pronounced genomic instability that is observable in both early 
and late stages of disease progression (Hingorani et al. 2005; Hruban et al. 2008; 
Campbell et al. 2010). This aggressive instability is driven at least partly by a high 
prevalence of telomere shortening and tumor suppressor loss in early PanINs. Combined 
with the hypoxic, ischemic and inflammatory microenvironment around PanINs, this 
suggests that pancreatic cancer cells innately possess a robust mutator phenotype and 
experience significant selective pressure at baseline. In such a setting, preserving miRNA 
function could be advantageous by providing robustness to an already highly 
dysfunctional cellular physiology. Indeed, given the long timeline of pancreatic cancer 
development and the high rate of passenger mutations known to occur in disease 
progression, loss of translational control by impaired miRNA biogenesis could be lethal 
by suddenly exposing cumulative mutations in gene regulatory elements to selective 
pressure. Similarly, a pancreatic cell line engineered to have baseline deficiencies in 
miRNA biogenesis may be less capable of coping with acute stress due to aggressively 
mutated gene regulatory elements that promote aberrant gene expression when 
translational precision is needed. Considering this, it could make a great deal of sense that 
DPC cell lines would be less able to cope with the intensely selective pressure of anoikis 
compared to PC lines, which would be predicted to have higher levels of miRNA 
processing and therefore more robust control of their transcriptional response to stress. 
Profiling of human pancreatic cancers has to date focused on gene amplifications, 
chromosomal rearrangements, miRNA profiles, and the analysis of transcriptomes and 
proteomes (Buchholz et al. 2005; Prasad et al. 2005; Lee et al. 2007; Jones et al. 2008; 
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Zhang et al. 2009; Campbell et al. 2010; Yachida et al. 2010; Que et al. 2013; Kim et al. 
2014). However, no comprehensive study of mutations in upstream genetic elements 
including promoters and regulatory elements has yet been performed. Perhaps such an 
analysis would reveal a higher than average rate of mutations in pancreatic cancers in 
these genomic regions compared to other carcinomas, which might suggest a need for 
downstream regulation of gene expression by miRNAs. Hypomethylation of gene 
promoters is known to increase gene expression in cancer, and could exert selective 
pressure to maintain miRNA biogenesis as a means to balance deregulated transcription. 
However, evidence exists to support both hypermethylation as well as hypomethylation 
of gene promoters in pancreatic cancer, suggesting that the apparent requirement for 
miRNA biogenesis in this context is not related to the widespread hypomethylation of 
gene promoters (Omura et al. 2008; Tan et al. 2009; Yi et al. 2013). Further work is 
needed to determine the impact of passenger mutations in pancreatic cancer and what 
relationship they may play in governing transcriptional control. Such an analysis could 
lead to an improved understanding of the broad need for miRNA biogenesis in pancreatic 
cancer. 
 
Final thoughts 
The results of this study indicate that Dicer plays an important role in conferring 
physiological robustness to pancreatic cells, both in normal tissue homeostasis as well as 
in a cancer context. I have thoroughly characterized the behavior of a large panel of 
cancer cell lines from the tumor study, and have demonstrated a deficit in anoikis 
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resistance for DPC cell lines that aligns with the metastasis deficiency of DPC tumors. 
However, the mechanism of this deficiency remains to be determined. I have discussed 
the potential for general miRNA expression levels to buffer cellular responses to stress, 
but I have not yet determined whether specific miRNA-mRNA relationships could be 
differentially regulated in DPC cells that would explain their sensitivity to anoikis. 
In pursuit of this, I am collaborating with Mike Lee to perform multivariate 
analysis of small RNA sequencing from five PC cell lines and five DPC cell lines. The 
goal of this analysis is to compare each cell line’s miRNA expression profile to its 
phenotypic profile and determine across the entire set if predictive relationships exist 
between particular miRNAs and particular phenotypes. Our hope is that we will discover 
miRNA networks that could implicate particular cellular pathways or proteins in the 
anoikis resistance of PC cell lines. We could then validate a model based on these 
relationships by analyzing the miRNA expression of cell lines which have been 
phenotypically characterized but were not included in the sequencing set. However, if no 
relationships exist between the sequencing data and the degree of anoikis resistance, it 
would suggest that this phenotype is governed by something that we have yet to measure. 
This scenario could support the miRNAs-as-buffers model previously discussed, but that 
would also be very difficult to validate, requiring fairly nuanced biochemical analyses of 
a large number of cell lines to determine differences in transcriptional and translational 
rates in response to stress. It will certainly be interesting to see where the data leads over 
the next few months. 
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Materials and Methods 
Cell Culture 
 All cell lines were grown in high glucose DMEM (Life Technologies #11965) 
supplemented with 10% fetal bovine serum (Atlanta Biologicals #s11150) and 100U/ml 
penicillin/streptomycin (Life Technologies #15140). Cell lines were maintained at 
subconfluent densities on tissue culture-treated dishes and periodically thawed fresh from 
frozen stocks to maintain low passage number. 
 Proliferation, migration, invasion, serum starvation, and soft agar colony 
formation assays were carried out as described previously (Chapter II; Materials and 
Methods). Gemcitabine survival experiments were plated at 105 cells per well of a 24-
well plate and allowed to adhere for 24 hours prior to treatment with 200nM gemcitabine. 
Forty-eight hours after treatment, live and dead cells were counted by trypan blue 
exclusion. Anoikis assays were performed by plating a suspension of 2.5x105 cells per 
well of a 24-well plate pre-coated with poly(2-hydroxyethyl methacrylate) (‘poly-
HEMA’; Sigma-Aldrich #P3932). Suspended cells were plated in a 1:1 mixture of 2x 
complete media and 2% methylcellulose to prevent cell-cell interactions (Sigma-Aldrich 
#M7140). Twenty-four hours after plating, cells were collected, separated from 
methylcellulose medium by centrifugation and counted by trypan blue exclusion. 
 DF1 chicken fibroblasts were maintained at 39˚C in a humidified tissue culture 
incubator. Production of RCAS virus was initiated by transfection of 5ug of RCAS-
PyMT into a subconfluent 10cm plate of cells using Superfect (QIAGEN #301305). Viral 
titers were confirmed by serial dilution of viral supernatant onto naïve DF1 cells and PCR 
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of genomic DNA to confirm the presence of the RCAS envelope protein. Titers were 
required to be high enough to generate detectable infection of naïve DF1 cells at a 
dilution of 1:2x107. Prior to injection into mice, cells were trypsinized, suspended in 
complete media, and counted. Cells were then pelleted by centrifugation and suspended 
in serum-free media at a final concentration of 1x108 cells/ml. Primer sequences for the 
RCAS PCR reactions are: Forward: CAGTCTCTCCCTAACATTAC; Reverse: 
CTACCTTGTGTGCTGTCGACC. 
 
Histological Stains 
 Mouse tissues were fixed, processed, cut and stained as described previously 
(Chapter II; Materials and Methods).  
 
Mouse Breeding, Euthanasia, and Necropsy 
 All mice generated in this study were housed in a dedicated facility in accordance 
with guidelines set forth by the Institutional Animal Care and Use Committee. The alleles 
for Ptf1a-Cre (Kawaguchi et al. 2002), Tp53flox (Jonkers et al. 2001), and Dicerflox 
(Mudhasani et al. 2008) have been described previously. Dicerflox mice were a generous 
gift from Steve Jones at the University of Massachusetts. 
 For the tumor study, Elastase-tva, Dicerflox, Tp53flox mice were bred to 
homozygosity and subsequently crossed Elastase-tva, Dicerflox/wt, Tp53flox/flox mice to 
generate littermate PC and DPC animals. Three day-old pups were injected with DF1 
chicken fibroblasts producing high-titer RCAS-PyMT, as previously described (Ahronian 
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and Lewis 2014). Animals were then monitored as described above for signs of illness 
and euthanized appropriately. 
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APPENDIX A 
Preclinical Assessment of a Triple-Drug Regimen for the Treatment of PDAC 
 
Introduction 
 Preclinical trials are absolutely necessary for the discovery of new therapeutic 
regimens to treat advanced pancreatic cancer. The work of a previous graduate student in 
the lab, Victoria Appleman, demonstrated that KRASG12D or BRAFV600E-driven pro-
survival signals are partly mediated by autocrine signaling through the IGF1 receptor 
(IGF1R) by IGF2 (Appleman et al. 2012). She demonstrated that pancreatic cancer cells 
are resistant to inhibitors of MEK or IGF1R signaling when given singly, but a 
combination of the two inhibitors can stimulate growth arrest and cell death. Based on 
these promising data, we decided to attempt the therapeutic treatment of mice using MEK 
and IGF1R inhibitors in combination with gemcitabine. 
We designed and executed a two-step preclinical trial beginning with a toxicity 
study to explore the tolerability of a variety of treatment regimens. Based on the results of 
the toxicity study, a treatment study was performed that suggests a slight benefit of 
combined MEK/IGF1R treatment with gemcitabine over gemcitabine alone, but these 
data do not achieve significance. This study requires follow-up to confirm treatment 
efficacy in target tissues and to explore whether adaptations in tumors reflect selective 
pressure to overcome the intervention. The completion of this study will inform our 
understanding of the therapeutic potential for IGF1R inhibition in the treatment of 
pancreatic cancer. 
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Results 
We first performed a toxicity trial in healthy C57/Bl6 animals to investigate the 
tolerability of various experimental cocktails of MEK and IGF1R inhibitors with 
gemcitabine. The dosages and abbreviations for these cocktails are given in Table A.1. 
Four mice were enrolled into each of the twelve arms of the study. We chose to use the 
inhibitors in a daily gavage regimen to limit toxicity associated with less frequent larger 
doses and also to enhance pharmacological efficacy. The IGF1R inhibitor BMS-754807 
and the MEK inhibitor PD-0325901 were used at 50 and 5mg/kg/day, respectively. We 
additionally tested two gemcitabine dosages: 75 and 150mg/kg. Gemcitabine was 
delivered by intraperitoneal injection twice weekly, at least three days apart, at which 
time the animals were also weighed. Treatment proceeded for four weeks in age-matched 
C57/Bl6 mice specifically purchased from Jackson Labs for the study. At the end of four 
weeks, animals were euthanized and weighed, and samples were obtained for 
biochemical (serum, frozen pancreas and frozen liver) and histological profiling 
(pancreas, liver, kidney, bowel, heart, lungs). 
Overall, treatment regimens were well-tolerated as determined by weight 
maintenance and overall health (Figure A.1). PBG150 was deemed toxic because of 
ubiquitous weight loss and 50% mortality during treatment. Histological analysis of the 
tissues of these mice revealed unremarkable histology in the lungs, heart, kidneys and 
liver, but prominent dysplasia in bowel crypts (Figure A.2). Crypt dysplasia was 
observed in all high-dose gemcitabine groups and in low-dose gemcitabine combined 
with MEK inhibition (Table A.2), and consisted largely of enhanced nuclear  
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Table A.1 Drug regimen dosages. 
Drug dosing was based on an average mouse weight of 25g, such that a gavage of 100ul delivered 50 
and 5mg/kg of the BMS and PD drug, respectively. The two different gemcitabine dilutions in 
phosphate buffered-saline (PBS) were similarly calculated to deliver 75 or 150mg/kg in 100ul volume 
(i.e. 19 or 38mg/mL based on a 25g average body weight). 
Drug Regimen Code:
V P B PB G
75
PG
75
BG
75
PB
G
75
G
15
0
PG
15
0
BG
15
0
PB
G
15
0
Oral 
Gavage 
(100ul)
BMS-754807 in PEG:H2O + + + + + +
PEG:H2O + + + + + +
PD-0325901 in HPM-T + + + + + +
HPM-T + + + + + +
38mg/mL Gemcitabine in PBS + + + +
19mg/mL Gemcitabine in PBS + + + +
PBS + + + +
IP Inj. 
(100ul)

139 
 
 
   Table A.2 Histological analysis of tissues from the toxicity study. 
‘-’: unremarkable histology; ‘B’: Ballooning degeneration; ‘D’: Dysplasia; ‘I’: Adipose Inflammation; 
‘H’: Hydronephrosis 
Animal Pancreas Liver Kidneys Bowel Heart Lungs
V#1 - - - - - -
V#2 - - - - - -
V#3 - - - - - -
V#4 - - - - - -
P#1 - - - - - -
P#2 - - - - - -
P#4 - - - - - -
B#2 - B H - - -
B#3 - B - - - -
B#4 - B - - - -
PB#1 - B - - - -
PB#2 - B - - - -
PB#3 - B - - - -
PB#4 - B - - - -
G75#1 - - - - - -
G75#2 - - - - - -
G75#3 - - - - - -
G75#4 - - - - - -
PG75#1 - - - - - -
PG75#2 - - - - - -
PG75#3 - - H D - -
PG75#4 - - - D - -
BG75#1 - B - - - -
BG75#2 - B - - - -
BG75#4 - B - - - -
PBG75#1 - B - D - -
PBG75#2 - B - D - -
PBG75#3 I B - D - -
PBG75#4 I B - D - -
G150#2 - - - - - -
G150#3 - - - - - -
G150#4 - - - - - -
PG150#1 - - - - - -
PG150#2 - - - D - -
PG150#3 - B - D - -
BG150#1 I B - - - -
BG150#2 I B - D - -
BG150#3 I B - D - -
BG150#4 I B - D - -
PBG150#1 - - - D - -
PBG150#2 I - - D - -
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euchromasia, disruption of nuclear polarity, inflammatory infiltrates, and increased cell 
death (Figure A.2b). Dysplasia was most severe in PBG150 animals, which also 
produced lightly colored, greasy stools, indicating malabsorption as a primary cause of 
weight loss. Additional histological findings relevant to treatment regimens included 
inflammation in the visceral adipose of PBG75, PBG150, and BG150 animals, which 
may be associated with tissue damage (Figure A.2e,f). Ballooning degeneration of 
hepatocytes was also observed in all mice treated with IGF1R inhibitor (Table A.2, 
Figure A.2d). Based on these data, PBG75 was chosen as the best-tolerated triple-drug 
regimen to be bested in the treatment study. 
During the treatment study, most mice maintained weight throughout treatment, 
with the notable exception of animals in the B cohort (Figure A.3). A disproportionate 
number of these animals succumbed to disease-related signs and symptoms (e.g. 
cachexia, jaundice, hunching, pain), but this association is not statistically significant. No 
statistically significant survival differences exist across the eight arms of the therapeutic 
trial, although there is the suggestion of a survival benefit of 22 days for the triple-
treatment regimen compared to gemcitabine alone (Figure A.4). 
Enrollment for the PBG groups was especially difficult due to occasional sepsis 
and death immediately following intraperitoneal injection (there were four iatrogenic 
mortalities for this group during enrollment). Necropsy of these animals revealed ascites 
and pruritic exudates in the IP cavity typically in the presence of an enlarged cecum that 
was visibly full of gas bubbles. Therefore death was due to the murine equivalent of 
ruptured appendicitis. This was most likely secondary to the small bowel pathology  
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Figure A.3 Weight trends are stable for low-dose triple-therapy; unopposed IGF1R 
inhibition carries higher tumor-related mortality. 
Weight measurements are plotted for the 21 days of active treatment. Asterisks highlight deaths 
related to disease during active therapy. 
* 
* * 
* 
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Figure A.4 No significant survival difference is seen with triple-drug therapy. 
There is an observable right-shift of 23 days in the survival curve of PBG-treated mice compared to 
gemcitabine alone, but the difference is not significant. 
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observed for this regimen in the toxicity study (i.e. malabsorption in the small intestine 
allowed nutrients to enter the large bowel, stimulating floral expansion and gas 
production and creating a toxic, enlarged cecum vulnerable to needle puncture). 
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Discussion 
 Targeting downstream pathways of KRAS signaling remains one of the most 
promising avenues of therapeutic intervention for the treatment of advanced pancreatic 
cancer. Initial work performed in vitro suggested efficacy against PDAC cell lines when 
treating with a combination of MEK and IGF1R inhibitors alongside gemcitabine, but our 
preclinical trial failed to generate statistically significant results. The data do suggest a 
benefit of an additional 22 days of survival for the PBG regimen, but the lack of 
statistical significance may simply indicate that our study was underpowered to detect 
this magnitude of a difference. A repeat trial focusing on this regimen with a higher 
enrollment could reveal if this difference is repeatable and significant. Indeed, in the 
treatment of pancreatic cancer, such a modest improvement in survival would be 
consistent with therapeutic advancements of the past, and should not be lightly discarded 
for being small in magnitude. However, prior to any repeat trials, a significant body of 
work remains to be completed with regards to immunohistochemical characterization of 
the tumors from this trial, specifically addressing ki67 and CC3 positivity and AKT, 
ERK, and IGF1R activity. It is reasonable to hypothesize that if the treatment did 
generate a partial clinical response, that the tumors which recovered after treatment may 
exhibit signs of a specific resistance to the therapy, including overexpression of IGF1R, 
EGFR, or MEK, hyper-activation of KRASG12D, or overexpression of members of the 
ABC family of multi-drug-resistance transporters. 
Future trials should also include a separate cohort of mice to be sacrificed on the 
last day of treatment, so that drug penetration and efficacy in tumor tissues can be 
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evaluated. One major factor in the chemotherapeutic resistance of pancreatic cancer is the 
physical barrier presented by the desmoplastic reaction around carcinoma cells. Dense 
networks of cross-linked collagen and a high oncotic pressure of the interstitial fluid 
inhibit drugs from diffusing out of the vasculature, through the stroma and into carcinoma 
cells (Neesse et al. 2011). This barrier is a significant challenge and several groups have 
sought ways of degrading it in order to improve drug access (Buckway et al. 2013; Meng 
et al. 2013). In lieu of such techniques, stromal investment must be accounted for when 
considering drug efficacy against a given tumor. Therefore stromal investment would 
need to be approximated by in vivo imaging at the time of enrollment in any future 
preclinical trials of the PBG regimen in order to accurately control for this variable across 
treatment groups. Together with a separate cohort for end-of-treatment histological 
analysis, this approach would yield definitive data on biochemical efficacy. 
 Another lingering curiosity from this study is the apparently more aggressive 
course of disease in animals treated with IGF1R inhibition alone (‘B’ groups). There is a 
20% chance that this observation is simply due to chance, according to a Fisher’s exact 
test, so a concrete interpretation is not strictly warranted, but if the finding is true, it does 
raise some concerns. For instance, in the three animals that died during treatment, all 
three exhibited severe signs of jaundice, although in one animal a tumor mass was not 
evident and in another the tumor was quite small, although all pancreata were notably 
fibrotic (data not shown). This may suggest a toxic effect of IGF1R inhibition against 
normal bile duct epithelium that only occurs in the context of a desmoplastic reaction. It 
is known that VEGF receptor signaling drives nitric oxide synthesis in endothelial cells to 
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stimulate smooth muscle cell relaxation (Isenberg et al. 2009), and perhaps (by an 
admittedly generous leap of the imagination) there exists a similar paracrine signaling 
between the normal bile duct epithelium and the investing desmoplastic stroma of the 
neoplastic pancreas, such that IGF1R inhibition results in pronounced bile duct stricture. 
Perhaps more simply, given that neoplastic cells escape the epithelial compartment 
during ADM and take on myofibroblast morphology (Rhim et al. 2012), this may suggest 
that IGF1R inhibition triggers contraction of these cells, perhaps through activation of 
PKC, although the mechanism of that interaction would contradict a classical view of 
RAS signaling. To date there are no studies suggesting any such relationship, but given 
that jaundice is a mitigating factor in recovery from pancreatic surgery (Roque et al. 
2015), this may be a worthwhile field of exploration. 
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Materials and Methods 
 
Mouse Breeding, Dosing, Euthanasia, and Necropsy 
 All mice generated in this study were housed in a dedicated facility in accordance 
with guidelines set forth by the Institutional Animal Care and Use Committee. The alleles 
for Ptf1a-Cre (Kawaguchi et al. 2002), LSL-KrasG12D (Jackson et al. 2001), and Tp53flox 
(Jonkers et al. 2001) have been described previously. 
 For the toxicity study, pure C57/Bl6 strain mice were obtained from Jackson Labs 
at ages between six and eight weeks. For the intervention study, Tp53flox/flox, LSL-
KrasG12D mice on a mixed background were crossed to Ptf1a-Cre mice on a C57/Bl6 
background to generate LSL-KrasG12D, Tp53flox/wt, Ptf1a-Cre mice for enrollment. 
 Health status was monitored at least three times per week for all animals and 
weights were measured on Mondays and Fridays for the duration of treatment in both 
studies. Major signs of illness warranting euthanasia included severely reduced mobility 
with lack of arousal upon handling, hunching, abdominal distension, wasting, palpable 
abdominal mass, hyperventilation, and weight loss greater than 10% of total body weight 
in 24 hours. Notes were recorded regarding external and internal signs of illness and 
samples were processed as previously described (see Chapter II, Materials and Methods).  
Drug administration via daily oral gavage was performed by trained animal 
medicine staff. Drugs were prepared and delivered twice weekly to the mouse room for 
use by animal medicine to ensure optimum inhibitor stability and efficacy. Intraperitoneal 
injections were performed on Mondays and Fridays using a 28 gauge insulin syringe. 
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Drug Preparation 
The IGF1R inhibitor BMS-754807 is dissolved in a 4:1 mixture of polyethylene 
glycol (PEG) and water. This occurs by first vortexing the desired amount of drug in a 
volume of PEG equal to 80% of the desired final volume until drug clumps have 
dissociated. Water is then added to bring the solution to its final volume and vortexing is 
continued for one minute to ensure complete solvation of the drug. The solution can then 
be 0.45um filter sterilized and is shelf-stable for several weeks at 4˚C. 
The MEK inhibitor PD-0325901 is dissolved in a 0.5% solution of 
hydroxypropylmethylcellulose (HPM) supplemented with 0.2% Tween-80 (‘HPM-T’). 
HPM powder disperses into water at high temperatures and dissolves at lower 
temperatures, and the final solution cannot be filter sterilized. Therefore assembling the 
liquid vehicle for the PD drug takes place in the hood and requires sterile technique. 
Briefly, an excess of water is heated to near-boiling on a stirrer-hot plate in the hood. A 
second flask is assembled with a stirring rod and the desired amount of HPM powder. 
With constant stirring, the desired volume of hot water is added to the HPM powder and 
allowed to mix until the powder has completely dispersed and there are no clumps. This 
solution is then allowed to cool very slowly to room temperature with stirring, upon 
which the HPM goes into solution. Tween-80 is then added and the HPM-T is left to stir 
overnight. PD drug is suspended in HPM-T by sonication, and stocks require periodic 
sonication to resuspend precipitated drug. Drug aliquots were sonicated and delivered to 
the animal facility every other day to prevent precipitation prior to gavage.  
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